Ainos (AIMD) S-1/A 27 Jul 22 IPO registration (amended) Financial data

Cover

Cover	3 Months Ended
	Mar. 31, 2022
Cover [Abstract]
Entity Registrant Name	AINOS, INC.
Entity Central Index Key	0001014763
Document Type	S-1/A
Amendment Flag	true
Entity Small Business	true
Amendment Description	Amendment.
Entity Emerging Growth Company	false
Entity Filer Category	Non-accelerated Filer
Entity Incorporation State Country Code	TX
Entity Tax Identification Number	75-1974352
Entity Address Address Line 1	8880 Rio San Diego Drive, Ste. 800
Entity Address City Or Town	San Diego
Entity Address State Or Province	CA
Entity Address Postal Zip Code	92108
City Area Code	858
Local Phone Number	869-2986

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 1,871,349	$ 1,751,499	$ 22,245
Inventory	337,805	0
Other current assets	813,905	466,198	54,168
Total current assets	3,023,059	2,217,697	76,413
Intangible assets, net	36,214,023	37,329,191
Property and equipment, net	1,419,584	1,187,702	3,249
Intangible Assets, Net		37,329,191	180,628
Other assets	79,598	87,571	0
Total assets	40,736,264	40,822,161	260,290
Current Liabilities:
Notes payable	1,013,405	213,405	218,010
Payables - related party	0	26,000,000	0
Convertible notes payable	3,376,526	3,376,526	734,991
Accrued expenses and others current liabilities	1,339,585	1,004,868	145,567
Total current liabilities	5,729,516	30,594,799	1,098,568
Long term liabilities:
Convertible notes payable - noncurrent	26,900,000	0
Operating lease liabilities - noncurrent	24,152	30,255
Total long term liabilities	26,924,152	30,255	0
Total liabilities	32,653,668	30,625,054	1,098,568
Stockholders' Equity (deficit)
Preferred stock, $0.01 par value; 10,000,000 shares authorized; none issued	0	0	0
Common stock, $0.01 par value; 300,000,000 shares authorized as of March 31, 2022 and December 31, 2021; 144,379,308 shares issued and outstanding as of March 31, 2022 and December 31, 2021	96,252	96,252	420,662
Additional paid-in capital	20,247,414	20,203,971	4,961,315
Accumulated deficit	(12,208,811)	(10,108,916)	(6,220,255)
Translation adjustment	(52,259)	5,800	0
Total stockholders' equity	8,082,596	10,197,107	(838,278)
Total liabilities and stockholders' equity	$ 40,736,264	$ 40,822,161	$ 260,290

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2022	Dec. 31, 2021	Dec. 30, 2021	Dec. 31, 2020
Condensed Consolidated Balance Sheets
Preferred Stock, Par Value (in Dollars Per Share)	$ 0.01	$ 0.01	$ 0.01	$ 0.01
Preferred Stock, Shares Authorized (in Shares)	10,000,000	10,000,000	10,000,000,000,000	10,000,000
Preferred Stock, Shares Issued (in Shares)	0	0	0	0
Preferred Stock, Shares Outstanding (in Shares)		0		0
Common Stock, Par Value (in Dollars Per Share)	$ 0.01	$ 0.01	$ 0.01	$ 0.01
Common Stock, Shares Authorized (in Shares)	300,000,000	300,000,000	300,000,000	100,000,000
Common Stock, Shares Issued (in Shares)	144,379,308	144,379,308	144,379,308	42,066,172
Common Stock, Shares Outstanding (in Shares)	144,379,308	144,379,308	144,379,308	42,066,172

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021	Dec. 31, 2020
Condensed Consolidated Statements of Operations (Unaudited)
Revenues	$ 87,200	$ 2,121	$ 594,563	$ 16,563
Cost Of Revenues	(41,078)	(1,249)	(184,181)	(11,277)
Gross Margin	46,122	872	410,382	5,286
Operating Expenses:
Research And Development Expenses	1,577,454	0	1,920,645	389
Selling, General And Administrative Expenses	551,730	522,981	2,357,163	1,445,332
Total Operating Expenses	2,129,184	522,981	4,277,808	1,445,721
Operating loss	(2,083,062)	(522,109)	(3,867,426)	(1,440,435)
Non-operating income and expenses, net
Interest expenses, net	(16,687)	(11,897)	(18,689)	(10,185)
Other losses	(146)	0	(2,547)	(3)
Total non-operating income and expenses, net	(16,833)	(11,897)	(21,236)	(10,188)
Net loss	$ (2,099,895)	$ (534,006)	$ (3,888,661)	$ (1,450,623)
Basic and diluted net loss per average share available to common shareholders	$ (0.01)	$ (0.01)	$ (0.03)	$ (0.04)
Weighted average common shares outstanding- basic and diluted	144,379,308	42,066,172	113,270,245	40,730,934

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Condensed Consolidated Statements of Comprehensive Loss (Unaudited)
Net loss	$ (2,099,895)	$ (534,006)
Other comprehensive loss:
Translation adjustment	(58,059)	0
Comprehensive loss	$ (2,157,954)	$ (534,006)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) - USD ($)	Total	Common Stock	Preferred Stock	Additional Paid-In Capital	Retained Earnings (Accumulated Deficit)	Translation Adjustment	Other comprehensive loss [Member]
Balance, Amount at Dec. 31, 2019	$ (156,682)	$ 405,164	$ 0	$ 4,207,786	$ (4,769,632)	$ 0
Balance, Shares at Dec. 31, 2019		40,516,351
Issuance Of Stock For Compensation, Shares		1,149,821
Issuance Of Stock For Compensation, Amount		$ 11,498	0	283,192	0	0
Net loss	(1,450,623)	$ 0	0	0	(1,450,623)	0
Issuance Of Stock For Cash, Shares		400,000
Balance, Amount at Dec. 31, 2020	(838,278)	$ 420,662	$ 420,662	4,961,315	(6,220,255)	0
Balance, Shares at Dec. 31, 2020		42,066,172	42,066,172
Net loss	(534,006)				(534,006)
Share-based compensation	94,105			94,105
Balance, Amount at Mar. 31, 2021	(1,278,179)	$ 0	$ 420,662	5,055,420	(6,754,261)		$ 0
Balance, Shares at Mar. 31, 2021		42,066,172	42,066,172
Balance, Amount at Dec. 31, 2020	(838,278)	$ 420,662	$ 420,662	4,961,315	(6,220,255)	0
Balance, Shares at Dec. 31, 2020		42,066,172	42,066,172
Issuance Of Stock For Compensation, Shares		237,415
Net loss	(3,888,661)	$ 0	$ 0	0	(3,888,661)	0
Translation Adjustment	5,800	$ 0	0	0	0	5,800
Conversion Of Convertible Notes Into Common Stock, Shares		1,905,321
Conversion Of Convertible Notes Into Common Stock, Amount	476,329	$ 19,053	0	457,276	0	0
Issuance Of Common Stock For Intangible Assets, Shares		100,000,000
Issuance Of Stock For Options, Shares		170,400
Acquisition Of Intangible Assets And Equipment	(5,773,130)			(5,773,130)
Balance, Amount at Dec. 31, 2021	10,197,107	$ 1,443,793	0	18,856,430	(10,108,916)	$ 5,800	5,800
Balance, Shares at Dec. 31, 2021		144,379,308
Net loss	(2,099,895)		0		(2,099,895)
Share-based compensation	43,443		$ 0	43,443
Translation Adjustment	(58,059)						(58,059)
Balance, Amount at Mar. 31, 2022	$ 8,082,596	$ 0		$ 18,899,873	$ (12,208,811)		$ (52,259)
Balance, Shares at Mar. 31, 2022		144,379,308	144,379,308

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021	Dec. 31, 2020
Cash flows from operating activities:
Net Loss	$ (2,099,895)	$ (534,006)	$ (3,888,661)	$ (1,450,623)
Adjustments To Reconcile Net Loss To Net Cash Used In Operating Activities:
Depreciation And Amortization	1,168,773	3,905	2,044,447	14,698
Share-based Compensation Expense			(10,683)	374,337
Stock Issued For Compensation			160,978	150,440
Share-based compensation expense	43,443	94,105
Loss On Disposal Of Property, Plant And Equipment			2,223	0
Contract Liabilities			59,575	0
Changes In Operating Assets And Liabilities:
Inventory	(337,805)	3,024	(3,024)	(1,107)
Other current assets	(297,707)	18,254
Accrued expenses and others current liabilities	133,302	202,981
Prepaid Expense And Other Current Assets			(415,054)	(19,020)
Accounts Payable And Accrued Expenses			794,174	429,510
Acquisition of property and equipment	(135,899)	0
Net cash used in operating activities	(1,389,889)	(211,737)	(1,249,977)	(499,551)
Cash Flows From Investing Activities :
Proceeds from convertible notes payable	850,000	236,854
Patent Purchases			0	(7,243)
Proceeds from notes payable	800,000	0
Acquisition Of Property, Plant And Equipment			(143,792)	0
Net cash used in investing activities	(135,899)	0	(180,517)	(7,243)
Payments of other notes payable	0	(37,985)
Increase In Refundable Deposits And Others			(36,725)	0
Payments of lease liabilities	(5,116)	0	11,799	0
Cash Flows From Financing Activities :
Proceeds From Convertible Note Payable - Related Party			3,106,025	120,000
Payments Of Other Note Payable			(4,605)	0
Proceeds From Exercise Of Stock Options			64,752	0
Payments Of Lease Liabilities	5,116	0	(11,799)	0
Issuance of convertible notes for payables - related party	26,000,000	0
Receivable of convertible notes issued	50,000	0
Net change in equipment payable	202,002	0
Net cash provided by financing activities	1,644,884	198,869	3,154,373	120,000
Effect from foreign currency exchange	754	0	5,375	0
Net change in cash	119,096	(12,868)	1,723,879	(386,794)
Cash And Cash Equivalents At Beginning Of Period	1,751,499	22,245	22,245	409,039
Cash and cash equivalents at end of period	$ 1,871,349	$ 9,377	1,751,499	22,245
Supplemental Disclosures Of Noncash Financing And Investing Activities:
Cash Paid For Interest			19,380	855
Stock Issued For Subscription			0	100,000
Stock Issued For Patent Cost And Accrued Liabilities			0	144,250
Conversion Of Convertible Notes And Accrued Interest Into Common Stock			476,329	0
Rou Leased Assets			62,903	0
Acquisition Of Intangible Assets And Equipment			40,226,870	0
Decrease Of Additional Paid In Capital			5,773,130	0
Issuance Of Common Stock And Increase Of Current Liability			$ 46,000,000	$ 0

Organization and Business.

Organization and Business.	3 Months Ended
	Mar. 31, 2022
Organization and Business.
1. Organization and Business	1. Organization and Business.

Organization and Summary of Sig

Organization and Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2021
Organization and Summary of Significant Accounting Policies
Organization And Summary Of Significant Accounting Policies	1. Organization and Summary of Significant Accounting Policies Organization and Business We are engaged in developing medical technologies for point-of-care (“POCT”) testing and safe and novel medical treatment for a broad range of disease indications. Since our inception in 1984, we have concentrated our resources on business planning, raising capital, research and clinical development activities for our programs, securing related intellectual property and commercialization of proprietary therapeutics using low-dose non-injectable interferon (“IFN”). In addition to our core IFN technology, we are committed to developing a diversified healthcare business portfolio to include medical devices and consumer healthcare products. Although we have historically been involved in extensive pharmaceutical research and development of low-dose oral interferon as a therapeutic, we are prioritizing the commercialization of medical devices as part of our diversification strategy. Since the beginning of 2021, we have acquired significant intellectual property from our majority shareholder, Ainos KY, to expand our potential product portfolio into Volatile Organic Compounds (“VOC”) and COVID-19 POCTs. This includes 51 issued and pending patents related to VOC technologies and 3 issued patents for COVID-19 POCT products. We expect our underlying intellectual property to enable us to expedite the commercialization of our medical device pipeline, beginning with Ainos-branded COVID-19 POCT product candidates. Basis of Accounting The basis is United States generally accepted accounting policies (“U.S. GAAP”). Going Concern These financial statements have been prepared in accordance with United States generally accepted accounting principles (“U.S. GAAP”) applicable to a going concern, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. The Company has generated minimal revenue and has an accumulated deficit totaling $10,108,916 since inception. These factors, among others, indicate that there is substantial doubt about the Company’s ability to continue as a going concern within one year from the issuance date of this filing. In order to obtain the necessary capital to sustain operations, management’s plans include, among other things, the possibility of pursuing new equity sales and/or making additional debt borrowings, There can be no assurances, however, that the Company will be successful in obtaining additional financing, or that such financing will be available on favorable term, if at all. Obtaining commercial loans, assuming those loans would be available, will increase the Company’s liabilities and future cash commitments. If the Company is unable to obtain financing in the amounts and on terms deemed acceptable, the business and future success may be adversely affected and the Company may cease operations. These factors raise substantial doubt regarding our ability to continue as a going concern. The accompanying financial statements do not include any adjustments relative to the recoverability and classification of asset carrying amounts or the amount and classification of liabilities that might result from the outcome of this uncertainty. Fair Value of Financial Instruments Under the Financial Account Standards Board Accounting Standards Codification (“FASB ASC”), we are permitted to elect to measure financial instruments and certain other items at fair value, with the change in fair value recorded in earnings. We elected not to measure any eligible items using the fair value option. Consistent with the Fair Value Measurement Topic of the FASB ASC, we implemented guidelines relating to the disclosure of our methodology for periodic measurement of our assets and liabilities recorded at fair market value. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. A three-tier fair value hierarchy prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurements) and the lowest priority to unobservable inputs (level 3 measurements). These tiers include: · Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets; · Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and · Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one more significant inputs or significant value drivers are unobservable. Our Level 1 assets and liabilities primarily include our cash and cash equivalents. Valuations are obtained from readily available pricing sources for market transactions involving identical assets or liabilities. The carrying amounts of accounts receivable, prepaid expense, accounts payable, accrued liabilities, advances from investors, and notes payable approximate fair value due to the immediate or short-term maturities of these financial instruments. Stock-Based Compensation Stock-based compensation expense is recorded in accordance with FASB ASC Topic 718, Compensation - Stock Compensation Cash and Cash Equivalents The Company classifies investments as cash equivalents if the original maturity of an investment is three months or less. Revenue Recognition We account for revenue from contracts with customers in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Update (“ASU”) No. 2014-09, “Revenue from Contracts with Customers (“Topic 606”).” The unit of account in Topic 606 is a performance obligation, which is a promise in a contract to transfer to a customer either a distinct good or service (or bundle of goods or services) or a series of distinct goods or services provided at a point in time or over a period of time. Topic 606 requires that a contract’s transaction price, which is the amount of consideration to which an entity expects to be entitled in exchange for transferring promised goods or services to a customer, is to be allocated to each performance obligation in the contract based on relative standalone selling prices and recognized as revenue when (point in time) or as (over time) the performance obligation is satisfied. Total revenues include sales of products to customers, net of discounts or allowances, if any, and include freight and delivery costs billed to customers. Revenues for product sales are recognized when control of the promised good is transferred to unaffiliated customers, typically when finished products are shipped. Shipping costs are deemed fulfillment costs and are not recognized as a separate performance obligation. Allowance for Doubtful Accounts The Company establishes an allowance for doubtful accounts to ensure trade and notes receivable are not overstated due to non-collectability. The Company’s allowance is based on a variety of factors, including age of the receivable, significant one-time events, historical experience, and other risk considerations. The Company had no material accounts receivable and no allowance at December 31, 2021 or 2020. Inventory Inventories are stated at the lower of cost or market. Cost is determined on a first-in, first-out basis. The Company continually assesses the appropriateness of inventory valuations giving consideration to slow-moving, non-saleable, out-of-date or close-dated inventory. Property and Equipment Property and equipment are stated on the basis of historical cost less accumulated depreciation. Depreciation is provided using the straight-line method over the two to seven year estimated useful lives of the assets. Patents and Patent Expenditures The Company holds patent license agreements and maintains patents that are owned by the Company. All patent license agreements remain in effect over the life of the underlying patents. Accordingly, the patent license fee is being amortized over the estimated life of the patent using the straight-line method. Patent fees and legal fees associated with the issuance of new owned patents are capitalized and amortized over the estimated 8 to 20 year life of the patent. The Company continually evaluates the amortization period and carrying basis of patents to determine whether subsequent events and circumstances warrant a revised estimated useful life or impairment in value. No patent costs were written off for the years ended December 31, 2021, or December 31, 2020. Income Taxes The asset and liability approach is used to account for income taxes by recognizing deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the carrying amounts and the tax bases of assets and liabilities. The Company records a valuation allowance to reduce the deferred tax assets to the amount that is more likely than not to be realized. Research and Development Internal research and development (“R&D”) costs are expensed as incurred. Clinical trial costs incurred by third parties are expensed as the contracted work is performed. Where contingent milestone payments are due to third parties under research and development collaborations, prior to regulatory approval, the payment obligations are expensed when the milestone results are achieved. Payments made to third parties subsequent to regulatory approval are capitalized as intangible assets and amortized to cost of products sold over the remaining useful life of the related product. Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Basic and Diluted Net Income (Loss) Per Share The basic earnings (loss) per share is calculated by dividing the Company’s net income (loss) available to common shareholders by the weighted average number of common shares issued and outstanding during the year. The diluted earnings (loss) per share is calculated by dividing the Company’s net income (loss) available to common shareholders by the diluted weighted average number of shares outstanding during the year. The diluted weighted average number of shares outstanding is the basic weighted number of shares adjusted as of the first year for any potentially dilutive debt or equity. As of December 31, 2021, potentially dilutive shares are not included in the calculation of fully diluted net loss per share as the effect with a net loss would be antidilutive. Concentration of Credit Risk Financial instruments that potentially subject the Company to significant concentration of credit risk consist principally of cash. The Company has cash balances in a single U.S. financial institution which, from time to time, could exceed the federally insured limit of $250,000. The Company maintains multiple accounts in its Taiwan Branch office which help to mitigate risk. Our bank deposits in Taiwan are insured by the Central Deposit Insurance Corp. (“CDIC”) with an insured limit of NT$3,000,000 per account. No loss has been incurred related to the aforementioned concentration of cash. Recent Accounting Pronouncements There have been no new accounting pronouncements issued or adopted during the year ended December 31, 2021 that are of significance to us.

Basis of presentation

Basis of presentation	3 Months Ended
	Mar. 31, 2022
Basis of presentation
2. Basis of presentation	2. Basis of presentation.

Property, Equipment, net

Property, Equipment, net	12 Months Ended
	Dec. 31, 2021
Property, Equipment, net
Property, Equipment And Software, Net	2. Property and Equipment, net Property and equipment are stated at cost less accumulated depreciation and consist of the following at December 31, 2021 and 2020: December 31, 2021 2020 Machinery and equipment $ 938,047 $ - Furniture and fixture 47,960 107,549 Construction in process 232,729 - Total cost 1,218,736 107,549 Less: accumulated depreciation (31,034 ) (104,300 ) Property and equipment, net $ 1,187,702 $ 3,249 Depreciation expense for the year ended December 31, 2021 and 2020 was $31,395 and $1,820, respectively. Construction in process represents assets that are not available for their intended use as of the balance sheet date. Net property and equipment were $1,187,702 and $3,249 as of December 31, 2021 and 2020, respectively. We acquired $944,152 of machinery and equipment from Ainos KY pursuant to the Asset Purchase Agreement entered in November 2021.

Patents, net

Patents, net	12 Months Ended
	Dec. 31, 2021
Patents, net
Patents, Net	3. Intangible assets, net Intangible assets are stated at cost less accumulated amortization and consist of the following at December 31, 2021 and 2020: December 31, 2021 2020 Patents and technology $ 39,371,317 $ 245,898 Less: accumulated amortization (2,042,126 ) (65,270 ) Patents and technology, net $ 37,329,191 $ 180,628 Amortization expense amounted to $2,000,302 for the year ended December 31, 2021 and $12,878 for the year ended December 31, 2020 respectively, and is included in R&D, selling, general and administrative expenses. Patents were $37,329,191 and $180,628 as of December 31, 2021 and 2020 respectively. We acquired intellectual properties related to VOC and COVID-19 technologies from Ainos KY pursuant to a Securities Purchase Agreement dated December 24, 2020, by and between the Company (under its former name “Amarillo Biosciences, Inc.”) and Ainos KY (the “Securities Purchase Agreement”) and the Asset Purchase Agreement. Estimated future amortization expense is as follows: 2022 4,522,141 2023 4,522,141 2024 4,534,493 2025 4,522,141 2026 4,521,973 Thereafter 14,706,301 Total expense $ 37,329,191

Convertible Notes Payable

Convertible Notes Payable	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Convertible Notes Payable
Convertible Notes Payable	6. Current Convertible Notes Payable and Other Notes Payable. Payee No. Effective Date Due Date From Effective Following Maturity Conversion Rate Issuing Purpose As of 12/31/2021 Addition Payment As of 3/31/2022 Accrued Interest Current Convertible Notes Payable: Stephen Chen #1.16 1/30/2016 Payable on demand 0.75% N/A $ 0.17 working capital 114,026 - - 114,026 6,050 Stephen Chen #2.16 3/18/2016 Payable on demand 0.65% N/A $ 0.19 working capital 262,500 - - 262,500 10,298 376,526 - - 376,526 16,348 Ainos KY #12.21 4/27/2021 2/28/2023 (1) 1.85% N/A $ 0.20 working capital 15,000 - - 15,000 257 Ainos KY #13.21 5/5/2021 2/28/2023 (1) 1.85% N/A $ 0.20 working capital 20,000 - - 20,000 335 Ainos KY #14.21 5/25/2021 2/28/2023 (1) 1.85% N/A $ 0.20 working capital 30,000 - - 30,000 471 Ainos KY #15.21 5/28/2021 2/28/2023 (1) 1.85% N/A $ 0.20 working capital 35,000 - - 35,000 545 Ainos KY #16.21 6/9/2021 2/28/2023 (1) 1.85% N/A $ 0.20 working capital 300,000 - - 300,000 4,486 Ainos KY #17.21 6/21/2021 2/28/2023 (1) 1.85% N/A $ 0.20 working capital 107,000 - - 107,000 1,535 Ainos KY #18.21 7/2/2021 2/28/2023 (1) 1.85% N/A $ 0.20 working capital 54,000 - - 54,000 744 Ainos KY #19.21 9/1/2021 2/28/2023 (1) 1.85% N/A $ 0.20 working capital 120,000 - - 120,000 1,289 Ainos KY #20.21 9/28/2021 2/28/2023 (1) 1.85% N/A $ 0.20 working capital 300,000 - - 300,000 2,798 Ainos KY #21.21 11/10/2021 2/28/2023 (1) 1.85% N/A $ 0.20 working capital 50,000 - - 50,000 357 Ainos KY #22.21 11/25/2021 2/28/2023 (1) 1.85% N/A $ 0.20 working capital 450,000 - - 450,000 2,851 Ainos KY #23.21 11/29/2021 2/28/2023 (1) 1.85% N/A $ 0.20 working capital 300,000 - - 300,000 1,840 Ainos KY #24.21 12/29/2021 2/28/2023 (1) 1.85% N/A $ 0.20 working capital 1,219,000 - - 1,219,000 5,684 3,000,000 - - 3,000,000 23,192 Total convertible notes payable- related parties 3,376,526 - - 3,376,526 39,540 Non-Convertible Notes Payable: Stephen Chen #9.21 1/1/2021 4/14/2021 0.13% N/A N/A working capital 129,405 - - 129,405 354 Ainos KY #26.22 (2) 3/4/2022 3/31/2023 1.85% N/A N/A working capital - 800,000 - 800,000 1,135 Non-convertible notes payable-related party 129,405 800,000 - 929,405 1,489 i2 China #8b.20 1/1/2020 1/1/2021 1.85% N/A N/A consulting fee 84,000 - - 84,000 3,527 Non-Convertible Notes payable- non-related party 84,000 84,000 3,527 Total non-convertible notes payable 213,405 800,000 - 1,013,405 5,016 Total convertible and non-convertible 3,589,931 800,000 - 4,389,931 44,556 Notes: (1) On March 17, 2022, we executed a Promissory Note Extension Agreement with Ainos KY in which the due dates for certain convertible notes enumerated as #12.21 to #24.21 issued by the Company to Ainos KY were extended to February 28, 2023. The total unpaid principal for these extended period convertible notes amount to $3,000,000 in the aggregate. (2) On March 11, 2022, the Board approved a Non-Convertible Note dated March 4, 2022 in favor of Ainos KY with a principal amount of $800,000, interest of 1.85% per annum on unpaid principal and accrued interest, and a maturity date of February 28, 2023. The Note includes standard provisions for notice, default, and remedies for default. All of the aforementioned convertible promissory notes and other notes payable are unsecured and due on demand upon maturity. The Company may prepay the notes in whole or in part at any time. The holder of convertible notes has the option to convert some or all of the unpaid principal and accrued interest to our common voting stock. The total interest expense of convertible notes payable and other notes payable for the three months ended March 31, 2022 and as of December 31 2021 was $15,883 and $11,897 respectively; the cumulative related accrued interest as of March 31, 2022 and December 31, 2021 were $44,556 and $28,673, respectively.	4. Convertible Notes Payable and Other Notes Payable All convertible and other notes payable were issued either as a result of financing or deferred compensation provided by executives of the Company. As of December 31, 2021 and December 31, 2020, convertible and other notes payable totaled $3,589,931 and $953,001, respectively; including notes payable for related parties totaling $3,505,931 and $805,001, respectively. Refer to disclosure in Note 5 below. The details of the convertible notes payable and other notes payable are shown in the table below: Payee No. Effective Date Due Date From Effective Following Maturity Conversion Rate Issuing Purpose 1/1/2021 Addition Payment 12/31/2021 Accrued Interest Convertible notes payable: Stephen Chen #1.16 1/30/2016 Payable on demand 0.75% NA $ 0.17 working capital 114,026 114,026 5,839 Stephen Chen #2.16 3/18/2016 Payable on demand 0.65% NA $ 0.19 working capital 262,500 262,500 9,878 Stephen Chen #3.19 912019 9/1/2020 1.85% 10% $ 0.25 salary 39,620 (39,620) 0 0 Stephen Chen #4.19 1212019 12/31/2020 1.61% 10% $ 0.25 working capital 14,879 (14,879) 0 0 Stephen Chen #6.20 112020 1/1/2021 1.85% 10% $ 0.25 salary 216,600 (216,600) 0 0 Stephen Chen #7.20 112020 1/2/2021 1.60% 10% $ 0.25 working capital 23,366 (23,366) 0 0 Stephen Chen #10.21 112021 4/1/2021 1.85% 1.85% $ 0.25 salary 59,025 (59,025) 0 0 Stephen Chen #11.21 412021 5/1/2021 1.85% 10% $ 0.25 salary 10,000 (10,000) 0 0 670,991 69,025 (363,490) 376,526 15,717 Ainos KY #12.21 4/27/2021 10/27/2021 1.85% NA $ 0.20 working capital 15,000 15,000 189 Ainos KY #13.21 5/5/2021 11/5/2021 1.85% NA $ 0.20 working capital 20,000 20,000 243 Ainos KY #14.21 5/25/2021 11/25/2021 1.85% NA $ 0.20 working capital 30,000 30,000 335 Ainos KY #15.21 5/28/2021 11/28/2021 1.85% NA $ 0.20 working capital 35,000 35,000 385 Ainos KY #16.21 6/9/2021 12/9/2021 1.85% NA $ 0.20 working capital 300,000 300,000 3,117 Ainos KY #17.21 6/21/2021 12/21/2021 1.85% NA $ 0.20 working capital 107,000 107,000 1,047 Ainos KY #18.21 7/2/2021 1/2/2022 1.85% NA $ 0.20 working capital 54,000 54,000 498 Ainos KY #19.21 912021 3/1/2022 1.85% NA $ 0.20 working capital 120,000 120,000 742 Ainos KY #20.21 9/28/2021 3/28/2022 1.85% NA $ 0.20 working capital 300,000 300,000 1,429 Ainos KY #21.21 11102021 5102022 1.85% NA $ 0.20 working capital 50,000 50,000 129 Ainos KY #22.21 11252021 11/25/2022 1.85% NA $ 0.20 working capital 450,000 450,000 798 Ainos KY #23.21 11/29/2021 5/29/2022 1.85% NA $ 0.20 working capital 300,000 300,000 471 Ainos KY #24.21 12292021 6/29/2022 1.85% NA $ 0.20 working capital 1,219,000 1,219,000 124 0 3,000,000 0 3,000,000 9,507 Total convertible notes payable- related parties 670,991 3,069,025 (363,490) 3,376,526 25,224 i2 China #5.19 9/1/2019 9/1/2020 1.85% 10% $ 0.25 consulting fee 16,000 (16,000) 0 0 i2 China #8a.20 1/1/2020 1/1/2021 1.85% 10% $ 0.25 consulting fee 48,000 (48,000) 0 0 i2 China #11.21 112020 4/1/2021 1.85% 10% $ 0.25 consulting fee 37,000 (37,000) 0 0 Total convertible notes payable- non-related party 64,000 37,000 (101,000) 0 0 Total Convertible notes payable 734,991 3,106,025 (464,490) 3,376,526 25,224 Notes payable: Stephen Chen #9.21 1/1/2021 4/14/2021 0.13% 10% NA working capital 134,010 145,395 (150,000) 129,405 312 Notes payable-related party 134,010 145,395 (150,000) 129,405 312 i2 China #8b.20 1/1/2020 1/1/2021 1.85% 10% NA consulting fee 84,000 84,000 3,137 Notes payable- non-related party 84,000 0 0 84,000 3,137 Total notes payable 218,010 145,395 (150,000) 213,405 3,449 Total convertible and non-convertible 953,001 3,251,420 (614,490) 3,589,931 28,673 All of the aforementioned convertible promissory notes and other notes payable are unsecured and due on demand upon maturity. The Company may prepay the notes in whole or in part at any time. The Payee has the option to convert some or all of the unpaid principal and accrued interest to our common voting stock. The convertible promissory notes are convertible on demand. The following convertible notes due to Stephen T. Chen - Notes 3.19, 4.19, 6.20, 7.20, 10.21, and 11.21 -- with a total principal and accrued interest amount of $372,988 were assigned by the holder to Top Calibre Corporation, a British Virgin Islands corporation, and subsequently converted in common stock of our company at a conversion price of $0.25 per share on December 27, 2021. No convertible notes were assigned in 2020. During 2021, the Company received funding from Dr. Stephen T. Chen and Ainos KY totaling $214,420 and $3,000,000, respectively. Amounts owed to Dr. Stephen T. Chen of $150,000 were repaid. In 2020, the Company received funding from Dr. Stephen T. Chen totaling $373,976. Note holders, i2China Management Group, LLC (“i2China”) and Dr. Stephen T. Chen (together the “Payees”), agreed to waive their rights pertaining to the conditional term “Annual Interest Rate on Matured, Unpaid Amounts: 10% per annum, compounded annually of Convertible Notes” in regards to interest charged on unpaid amounts following maturity for all of their respective notes. The Company and the Payees agree that the originally agreed annual interest rate will continue to be valid for any unpaid amounts after maturity. The amended terms of the above convertible notes and other notes payable were made during on September 1, 2021. Interest waived totaled $45,875. The total interest expense for 2021 and 2020 totaled $21,727 and $10,702 respectively; the cumulative related accrued interest as of December 31, 2021 and 2020 were $28,673 and $24,196, respectively.

Financial Condition

Financial Condition	3 Months Ended
	Mar. 31, 2022
Financial Condition
3. Financial Condition	3. Financial Condition. The continuing operations of the Company and the recoverability of the carrying value of assets is dependent upon the ability of the Company to obtain necessary financing to fund its working capital requirements, and upon future profitable operations. The accompanying financial statements do not include any adjustments relative to the recoverability and classification of asset carrying amounts or the amount and classification of liabilities that might result from the outcome of this uncertainty. There can be no assurance that capital will be available as necessary to meet the Company’s working capital requirements or, if the capital is available, that it will be on terms acceptable to the Company. The issuances of additional equity securities by the Company may result in dilution in the equity interests of its current stockholders. Obtaining commercial loans, assuming those loans would be available, will increase the Company’s liabilities and future cash commitments. If the Company is unable to obtain financing in the amounts and on terms deemed acceptable, the business and future success may be adversely affected and the Company may cease operations. These factors raise substantial doubt regarding our ability to continue as a going concern.

Non-Current Convertible Notes P

Non-Current Convertible Notes Payable	3 Months Ended
	Mar. 31, 2022
Non-Current Convertible Notes Payable
7.Non-Current Convertible Notes Payable	7. Non-Current Convertible Notes Payable. On January 30, 2022, we issued to Ainos KY a Convertible Promissory Note in the principal amount of $26,000,000 (the “APA Convertible Note”) for the Asset Purchase Transaction as more particularly described below in Item 8 in these Notes to Financial Statements. The principal sum of the APA Convertible Note is payable in cash on January 30, 2027, although we may prepay the APA Convertible Note in whole or in part without penalty. The APA Convertible Note is noninterest bearing. If not earlier repaid, the APA Convertible Note will be converted into shares of our common stock or such other securities or property for which the APA Convertible Note may become convertible, immediately prior to the closing of any public offering of our common stock as a result of which our common stock will be listed on a U.S. stock exchange. The conversion price, subject to certain adjustments, will be 80% of the initial public offering price of the offering. Convertible Note Offering Pursuant to Regulation S The Company issued Convertible Notes pursuant to certain Convertible Note Purchase Agreements under Regulation S. The transactions are more particularly described below: · $50,000 Convertible Note issued on March 31, 2022 to Yun-Han Liao. The purchaser is the daughter of Wu Hui-Lan, the Company’s Chief Financial Officer (the “Liao Convertible Note”). · $850,000 aggregate Convertible Notes issues on March 28, 2022 to Chih-Cheng Tsai, Ming-Hsien Lee, Yu-Yuan Hsu, and Top Calibre Corporation, a British Virgin Islands company (collectively the “Regulation S Notes”). · The Liao Convertible Note and the Regulation S Notes are collectively referred to as the “Convertible Notes”. The Principal Amount of the Convertible Notes are payable in cash on March 30, 2027, although the Company may prepay the Convertible Notes in whole or in part without penalty. The Convertible Notes are non-interest bearing. If not earlier repaid, the Convertible Notes will be converted into shares of common stock, $0.01 par value per share of the Company, or such other securities or property for which the Convertible Notes may become convertible, immediately prior to the closing of any public offering of the Company’s common stock as result of which the Company’s common stock will be listed on a U.S. stock exchange. The conversion price, subject to certain adjustments, will be eighty percent (80%) of the initial public offering price of the offering.

Related Party Transactions

Related Party Transactions	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Related Party Transactions
Related Party Transactions	8. Related Party Transactions. Asset Purchase Agreement Ainos KY and the Company entered into an Asset Purchase Agreement dated as of November 18, 2021 (the “Asset Purchase Agreement”), as modified by an Amended and Restated Asset Purchase Agreement dated as of January 29, 2022 (the “Amended Asset Purchase Agreement”). Pursuant to the Asset Purchase Agreement, the Company acquired certain intellectual property assets and certain manufacturing, testing, and office equipment for a total purchase price of $26,000,000. Pursuant to the Asset Purchase Agreement, the Company agreed to hire certain employees of Ainos KY who are responsible for research and development of the IP Assets and/or Equipment on terms at least equal to the compensation arrangements undertaken by Ainos KY. From and after the closing, we will have no responsibility, duty or liability with respect to any employee benefit plans of Ainos KY. As payment of the purchase price, we issued to Ainos KY a Convertible Promissory Note in the principal amount of $26,000,000 upon closing on January 30, 2022 (the “APA Convertible Note”). Refer to Note 7 of the Notes to Financial Statements for more information. Related Party Working Capital All convertible and other notes payable were issued either as a result of financing or deferred compensation provided by related parties. As of March 31, 2022 and December 31, 2021, the convertible and non-convertible notes payable for related parties totaled $4,355,931 and $3,505,931, respectively. Refer to Note 6 and 7 of the Notes to Financial Statements for more information. Purchase related to COVID-19 Antigen Rapid Test Kits We incurred costs associated with finished goods, raw materials and manufacturing fees for Covid-19 antigen rapid test kits from TCNT pursuant to a Sales and Marketing Agreement, totaling $386,412 for the three months ended March 31, 2022. There were no purchases from TCNT during the same period last year. Product Co-development Agreement Pursuant to the five-year product co-development agreement effective on August 1, 2021 with TCNT (the “Product Co-Development Agreement”) we incurred development expenses totaling $167,422 for the three months ended March 31, 2022 of which $109,131 is in accrued payable as of March 31, 2022. Promissory Note Extension Agreement On March 17, 2022, we executed a Promissory Note Extension Agreement with Ainos KY in which the due dates for certain convertible notes enumerated as #12.21 to #24.21 issued by the Company to Ainos KY were extended to February 28, 2023 (the “Promissory Note Extension Agreement”). The total unpaid principal for these extended period convertible notes amount to $3,000,000 in the aggregate. Refer to Footnote 1 of Note 6 of the Notes to Financial Statements for more information.	5. Related Party Transactions The following is a summary of related party transactions in 2021 and 2020 to which we have been a participant in which the amount involved exceeded or will exceed the lesser of $120,000 or 1% of the average of our total assets as of December 31, 2021 and 2020, and in which any of our directors, executive officers or holders of more than 5% of our capital stock, or any of our directors, executive officers or holders of more than 5% of our outstanding capital stock, or any immediate family member of, or person sharing the household with, any of these individuals or entities, had or will have a direct or indirect material interest, other than compensation arrangements which are described in Part II, Item 5 “Market for the Registrant’s Common Equity and Related Shareholder Matters, and Issuer Purchases of Equity Securities ,” Part III, Item 11 “Executive Compensation Name of the related party Relationship Description Taiwan Carbon Nano Technology Corporation (“TCNT”) Affiliated company TCNT is the majority shareholder of Ainos KY Ainos, Inc. (Cayman Island) (“Ainos KY”) Affiliated company Ainos KY is the majority shareholder of the Company ASE Technology Holding Affiliated company Sole owner of ASE Test Inc. which is Ainos KY’s board member and has more than 10% of the voting rights in Ainos KY Dr. Stephen T. Chen Ainos’ former Chairman, President, CEO and CFO Shareholder with more than 5% of the Company voting rights in 2021 and 2020 Purchase of intangible assets and equipment Securities Purchase Agreement On April 15, 2021, we consummated the Securities Purchase Agreement with Ainos KY. Pursuant to the Securities Purchase Agreement, we issued 100,000,000 shares of common stock at $0.20 per share to Ainos KY in exchange for certain patent assignments, increased its authorized common stock to 300,000,000 shares, and changed the Company’s name to “Ainos, Inc.” Immediately after the consummation of the transaction Ainos KY owned approximately 70.30% of the Company’s issued and outstanding shares of common stock. Asset Purchase Agreement On November 18, 2021, we entered into an Asset Purchase Agreement as modified by an Amended and Restated Asset Purchase Agreement dated as of January 29, 2022 (the “Asset Purchase Agreement”) with Ainos KY. We closed the transaction on January 30, 2022. See Notes 2, 3, and 12 for a discussion of the transaction. Related Party Financing All convertible and other notes payable were issued either as a result of financing or deferred compensation provided by shareholders. As of December 31, 2021 and 2020, the convertible notes payable and non-convertible notes payable for related parties totaled $3,505,931 and $805,001, respectively. Refer to Note 4 of the Notes to Financial Statements, which are incorporated herein by this reference, for more information. Other transactions COVID-19 Test Kits Sales and Marketing Agreement with Ainos KY On June 14, 2021, we entered into an exclusive agreement with Ainos KY to serve as the master sales and marketing agent for the Ainos COVID-19 antigen rapid test kit and COVID-19 nucleic acid test kits which are manufactured by TCNT. On June 7, 2021, the TFDA issued an emergency use authorization to TCNT for the Ainos COVID-19 antigen rapid test kit that will be sold and marketed under the “Ainos” brand in Taiwan. As TCNT secures regulatory authorizations from foreign regulatory agencies, we expect to partner with regional distributors to promote sales in other strategic markets. We purchased $183,444 of COVID-19 antigen rapid test kit inventory from TCNT for the year ended December 31, 2021 and $0 in 2020. Ainos - TCNT Product Development On August 1, 2021, we entered into a five-year product development agreement with TCNT. Pursuant to the agreement both parties will endeavor to work together to develop pharmaceutical, medical and preventive medicine related products, with the Company being the exclusive sales agent. We will bear the cost associated with product development and TCNT will make accessible its personnel and facilities. Both parties shall each jointly own the intellectual property rights of all research results of the co-development collaboration. As a result, we incurred product development expenses totaling $205,883 as of December 31, 2021 of which $65,156 is in accrued payable as of December 31, 2021 and $0 in product development expenses in 2020. COVID-19 Antigen Rapid Test Kits Sales We sold Covid-19 antigen rapid test kits to ASE Technology Holding totaling $209,468 for the year ended December 31, 2021 and $0 in 2020.

Common Stock

Common Stock	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Common Stock
Common Stock	4. Common Stock. We have not paid any dividends to our common stock shareholders to date, and have no plans to do so in the immediate future.	6. Common Stock We have 300,000,000 shares of voting common shares authorized for issuance. As of December 31, 2021, a total of 163,915,625 shares of common stock were either issued (144,379,308), reserved for conversion of convertible debt to stock (17,213,700), reserved for future issuance of RSUs for non-employee directors (1,320,000), held for future exercise of stock options (550,000) and shares reserved for warrant conversion (452,617). F-25 Table of Contents From January 1, 2021 to December 31, 2021, we granted common stock to the following: · On April 7, 2021, we issued 48,077 shares of common stock to Stephen T. Chen and/or Stephen T. Chen and Virginia M. Chen, Trustees, Stephen T. & Virginia M. Chen Living Trust Dated April 12, 2018 (Chen) as partial compensation payable for the period January 1, 2021 through March 31, 2021 under the Employment Agreement by and between the Company and Chen effective January 1, 2021 (“Chen Agreement”). · On April 7, 2021, we issued 5,769 shares of common stock to Bernard Cohen (“Cohen”) as partial compensation payable for the period January 1, 2021 through March 31, 2021 under the Employment Agreement by and between the Company and Cohen effective January 1, 2021 (“Cohen Agreement”). · On April 7, 2021, we issued 11,538 shares of common stock to Lawrence Lin (“Lin”) as compensation payable for the period January 1, 2021 through March 31, 2021 under the Consulting Agreement by and between the Company and Lin’s company, i2China Management Group, LLC, effective April 15, 2018 (“Lin Agreement”), as amended and made effective on January 1, 2020 (“Lin Amendment”). · On April 7, 2021, we issued 109,038 shares of common stock to John Junyong Lee as compensation payable for the period January 1, 2021 through March 31, 2021 under the Legal Retainer Agreement by and between the Company and Lee effective June 21, 2019 (“Lee Agreement”). · On April 15, 2021, we consummated the Securities Purchase Agreement and issued 100,000,000 shares of common stock at $0.20 per share to Ainos KY in exchange for certain patent assignments. · On June 30, 2021, we issued 5,342 shares of common stock as compensation payable for the period April 1, 2021 through April 15, 2021 under the Chen Agreement as amended by Amendment No. 2 that extended the termination date to April 15, 2021. · On June 30, 2021, we issued 107 shares of common stock to Bernard Cohen as compensation payable for the period April 1, 2021 through April 5, 2021 under the Cohen Agreement as amended by Amendment No. 1 that extended the termination date to April 5, 2021. · On June 30, 2021, we issued 3,846 shares of common stock to Lawrence Lin as compensation payable for the period April 1, 2021 through June 30, 2021 under the Lin Agreement and Lin Amendment. · On June 30, 2021, we issued 21,926 shares of common stock to John Junyong Lee as compensation payable for the period April 1, 2021 through June 30, 2021 under the Lee Agreement. · On July 30, 2021, we issued 20,000 shares of voting common stock to Ya-Ju (“Maggie Wang”), previously a branch manager of the Company’s Taiwan branch office. The Company received payment of $7,600 ($0.38 per share) in accordance to a Stock Option Agreement under the Company’s 2018 Employee Stock Option Plan. · On July 30, 2021, we issued 150,400 shares of voting common stock to Daniel Fisher, previously a Company board director. The Company received payment of $57,152 ($0.38 per share) in accordance to a Stock Option Agreement under the Company’s 2018 Officers, Directors, Employees and Consultants Nonqualified Stock Option Plan. · On December 27, 2021, we issued 1,491,953 shares of common stock to Top Calibre Corporation (“TCC”) resulting from an assignment of convertible promissory notes from Dr. Stephen T. Chen to TCC under that certain Assignment Agreement by and between Dr. Stephen T. Chen and TCC, dated December 15, 2021 (“TCC Agreement”). Convertible promissory notes #3.19, #4.19, #6.20, #7.20, #10.21 and #11.21 were exercised at its entirety at a strike price of $0.25 per share based on a combined aggregate principal and accrued interest amount of $372,988. · On December 27, 2021, we issued 413,368 shares of common stock to i2China Management Group LLC (“i2China”) resulting from a notice of demand from i2China to initiate the conversion of convertible promissory notes #5.19, #8.20a, and #11 exercised at its entirety at a strike price of $0.25 per share based on a combined aggregate principal and accrued interest amount of $103,342. · On December 27, 2021, we issued 2,946 shares of common stock to Lawrence Lin as compensation payable for the period July 1, 2021 through August 1, 2021 under the Lin Agreement and Lin Amendment. · On December 27, 2021, we issued 28,826 shares of common stock to John Junyong Lee as compensation payable for the period July 1, 2021 through September 31, 2021 under the Lee Agreement. We did not pay any dividends to its common stock shareholders in 2021 and has no plans to do so in the immediate future.

Preferred Stock

Preferred Stock	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Common Stock
Preferred Stock	5. Preferred Stock	7. Preferred Stock We have 10,000,000 shares of preferred stock authorized for issuance. No shares of preferred stock were outstanding as of December 31, 2021 and 2020 and none are outstanding as of the date of this report.

Stock Option and Stock Plans

Stock Option and Stock Plans	12 Months Ended
	Dec. 31, 2021
Stock Option and Stock Plans
Stock Option And Stock Plans	8. Stock Option and Stock Plans 2018 Employee Stock Option Plan (the “2018-ESOP”) On September 26, 2018, the Board adopted the Company 2018 Employee Stock Option Plan (the “2018-ESOP”), formerly referred to as the “Amarillo Biosciences, Inc., 2018 Employee Stock Option Plan” in prior filings. The 2018-ESOP provides for the grant of Qualified Incentive Stock Options to the Company’s employees. The Board, in its adoption of the 2018-ESOP, directed the Officers to submit the 2018-ESOP to the shareholders for ratification and approval at the next scheduled shareholders meeting. Failure of the ratification and approval of the 2018-ESOP within one year of the effective date renders the qualified options to become nonqualified options for purposes of the U.S Internal Revenue Code. A stockholders meeting was not convened within the one year period and, as a result, any qualified options automatically became non-qualified options effective September 26, 2019. The 2018-ESOP is administered by the Board or by a committee of directors appointed by the Board (the “Compensation Committee”) as constituted from time to time. The maximum number of shares of common stock which may be issued under the 2018-ESOP is 1,000,000 shares which will be reserved for issuance upon exercise of options. The option price per share of common stock deliverable upon the exercise of an incentive stock option is 100% of the fair market value of a share on the date of grant. The option price is $0.38 per share and the options are exercisable during a period of ten years from the date of grant, where the options vest 20% annually over five years, commencing one year from date of grant. Effective as of October 6, 2021, with the adoption by the Board of the 2021 SIP, no further awards may be granted under the 2018-ESOP. As of December 31, 2021, options to acquire 550,000 shares of common stock remained outstanding. 2018 Officers, Directors, Employees, and Consultants Nonqualified Stock Option Plan (the “2018-NQSOP”) On September 26, 2018, the Board adopted the Company 2018 Officers, Directors, Employees, and Consultants Nonqualified Stock Option Plan (the “2018-NQSOP”), formerly referred to as the “Amarillo Biosciences, Inc., 2018 Officers, Directors, Employees, and Consultants Nonqualified Stock Option Plan” in prior filings. The 2018-NQSOP provides for the grant of nonqualified incentive stock options to employees. The 2018-NQSOP is administered by the Board or by the Compensation Committee as constituted from time to time. The maximum number of shares of common stock which may be issued under the 2018-NQSOP is 4,000,000 which will be reserved for issuance upon exercise of options. The option price for the nonqualified options is $0.382 exercisable for a period of ten years, with a vesting period of five years at 20% per year commencing one year from date of grant. Effective as of October 6, 2021, with the adoption by the Board of the 2021 SIP, no further awards may be granted under the 2018-NQSOP. As of December 31, 2021, options to acquire 550,000 shares of common stock remained outstanding. Equity Compensation Plans Information: Stock Plans 1 Issue Date Range Total Options Authorized Options Issued Options Remaining 2 2018 Employee Stock Option Plan 3, 4 9/26/18 - 9/26/28 1,000,000 950,000 0 2018 Officers, Directors, Employees, and Consultants Nonqualified Stock Option Plan 3 9/26/18 - 9/26/28 4,000,000 4,495,000 5 0 ____________ 1 2 3 4 5 A summary of option activity for the years ended December 31, 2020 and December 31, 2021 are presented below. Date Number of Options 1 Number of Options Nonqualified Weighted Average Exercise Price Weighted Average Remaining Contractual Term Aggregate Intrinsic Value Balance December 31, 2019 850,000 3,807,000 $ 0.38 8 years - Exercised - - - - - Expired or Forfeited - - - - - Balance December 31, 2020 850,000 3,807,000 $ 0.38 7 years Granted 2021 - 500,000 $ 0.38 10 years Exercised 20,000 150,400 $ 0.38 - - Expired or Forfeited 780,000 3,656,600 $ 0.38 - - Balance December 31, 2021 50,000 500,000 $ 0.38 9.54 years - Vested as of December 31, 2021 30,000 0 $ 0.38 6.74 years - 1 The Company used the Black-Scholes option pricing model to value the option awards with the following assumptions applied: (1) Volatility - 276%; (2) Term - 5 years was chosen although the full option term is 10 years to be more commensurate with the 5-year vesting portion of the plan; (3) Discount - 2.96%. ____________ 2 See footnote 4 above. As of December 31, 2021, there is $410,022 in unrecognized option expense that will be recognized over the next 2.58 years. 2021 Employee Stock Purchase Plan On September 28, 2021, the Board approved the 2021 Employee Stock Purchase Plan (the “2021 ESPP” or “Plan”). The purpose of the 2021 ESPP is to provide an opportunity for eligible employees of the company and its designated companies (as defined in the Plan) to purchase common stock at a discount through voluntary contributions, thereby attracting, retaining and rewarding such persons and strengthening the mutuality of interest between such persons and the Company’s stockholders. The Company intends for offerings under the Plan to qualify as an “employee stock purchase plan” under Section 423 of the Code; provided, that the Plan administrator may also authorize the grant of rights under offerings that are not intended to comply with the requirements of Section 423, pursuant to any rules, procedures, agreements, appendices, or sub-plans adopted by the administrator. Subject to adjustments as provided in the Plan, the maximum number of shares of common stock that may be issued under the Plan may not exceed 750,000 shares. Such shares may be authorized but unissued shares, treasury shares or shares purchased in the open market. The Plan is be subject to approval by the Company’s stockholders within twelve months after the date of Board approval. The Plan will become effective on the date that stockholder approval is obtained, and will continue in effect until it expires on the tenth anniversary of the effective date of the Plan, unless terminated earlier. 2021 Stock Incentive Plan On September 28, 2021, the Board approved the 2021 Stock Incentive Plan (the “2021 SIP” or “Plan”). The purpose of the 2021 SIP is to provide a means through which the Company, and the other members of the Company Group, defined by Section 2(n) of the Plan as the Company and its subsidiaries, and any other affiliate of the Company designated as a member of the Company Group by the Committee, may attract and retain key personnel, and to provide a means whereby directors, officers, employees, consultants and advisors of the Company and the other members of the Company Group can acquire and maintain an equity interest in the Company, or be paid incentive compensation measured by reference to the value of common stock, thereby strengthening their commitment to the interests of the Company Group and aligning their interests with those of the Company’s stockholders. The types of awards that may be granted from the Plan include individually or collectively, any Incentive Stock Option, Nonqualified Stock Option, Stock Appreciation Right, Restricted Stock, Restricted Stock Unit, Dividend Equivalent Rights and Other Equity-Based Award granted under the Plan. The Plan will be effective upon shareholder approval. The expiration date of the Plan, on and after which date no awards may be granted, will be the tenth anniversary of the date of Board approval of the Plan, provided, however, that such expiration will not affect awards then outstanding, and the terms and conditions of the Plan will continue to apply to such Awards. The aggregate number of shares which may be issued pursuant to awards under the Plan is 20,000,000 shares of Common Stock (the “Plan Share Reserve”), subject to adjustments as provided in the Plan. The number of shares underlying any award granted under 2018 ESOP or 2018 NQSOP (the “Prior Plans”) that expires, terminates or is canceled or forfeited for any reason whatsoever under the terms of the Prior Plans, will increase the Plan Share Reserve. Each Award granted under the Plan will reduce the Plan Share Reserve by the number of shares underlying the award. No more than 10,000,000 shares may be issued in the aggregate pursuant to the exercise of incentive stock options granted under the Plan. The maximum number of shares subject to awards granted during a single fiscal year to any non-employee director, taken together with any cash fees paid to such director during the fiscal year, will not exceed $600,000 in total value (calculating the value of any such awards based on their grant date fair value for financial reporting purposes).

Current Convertible Notes Payab

Current Convertible Notes Payable and Other Related Party Notes Payable	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Convertible Notes Payable
6.Current Convertible Notes Payable and Other Related Party Notes Payable	6. Current Convertible Notes Payable and Other Notes Payable. Payee No. Effective Date Due Date From Effective Following Maturity Conversion Rate Issuing Purpose As of 12/31/2021 Addition Payment As of 3/31/2022 Accrued Interest Current Convertible Notes Payable: Stephen Chen #1.16 1/30/2016 Payable on demand 0.75% N/A $ 0.17 working capital 114,026 - - 114,026 6,050 Stephen Chen #2.16 3/18/2016 Payable on demand 0.65% N/A $ 0.19 working capital 262,500 - - 262,500 10,298 376,526 - - 376,526 16,348 Ainos KY #12.21 4/27/2021 2/28/2023 (1) 1.85% N/A $ 0.20 working capital 15,000 - - 15,000 257 Ainos KY #13.21 5/5/2021 2/28/2023 (1) 1.85% N/A $ 0.20 working capital 20,000 - - 20,000 335 Ainos KY #14.21 5/25/2021 2/28/2023 (1) 1.85% N/A $ 0.20 working capital 30,000 - - 30,000 471 Ainos KY #15.21 5/28/2021 2/28/2023 (1) 1.85% N/A $ 0.20 working capital 35,000 - - 35,000 545 Ainos KY #16.21 6/9/2021 2/28/2023 (1) 1.85% N/A $ 0.20 working capital 300,000 - - 300,000 4,486 Ainos KY #17.21 6/21/2021 2/28/2023 (1) 1.85% N/A $ 0.20 working capital 107,000 - - 107,000 1,535 Ainos KY #18.21 7/2/2021 2/28/2023 (1) 1.85% N/A $ 0.20 working capital 54,000 - - 54,000 744 Ainos KY #19.21 9/1/2021 2/28/2023 (1) 1.85% N/A $ 0.20 working capital 120,000 - - 120,000 1,289 Ainos KY #20.21 9/28/2021 2/28/2023 (1) 1.85% N/A $ 0.20 working capital 300,000 - - 300,000 2,798 Ainos KY #21.21 11/10/2021 2/28/2023 (1) 1.85% N/A $ 0.20 working capital 50,000 - - 50,000 357 Ainos KY #22.21 11/25/2021 2/28/2023 (1) 1.85% N/A $ 0.20 working capital 450,000 - - 450,000 2,851 Ainos KY #23.21 11/29/2021 2/28/2023 (1) 1.85% N/A $ 0.20 working capital 300,000 - - 300,000 1,840 Ainos KY #24.21 12/29/2021 2/28/2023 (1) 1.85% N/A $ 0.20 working capital 1,219,000 - - 1,219,000 5,684 3,000,000 - - 3,000,000 23,192 Total convertible notes payable- related parties 3,376,526 - - 3,376,526 39,540 Non-Convertible Notes Payable: Stephen Chen #9.21 1/1/2021 4/14/2021 0.13% N/A N/A working capital 129,405 - - 129,405 354 Ainos KY #26.22 (2) 3/4/2022 3/31/2023 1.85% N/A N/A working capital - 800,000 - 800,000 1,135 Non-convertible notes payable-related party 129,405 800,000 - 929,405 1,489 i2 China #8b.20 1/1/2020 1/1/2021 1.85% N/A N/A consulting fee 84,000 - - 84,000 3,527 Non-Convertible Notes payable- non-related party 84,000 84,000 3,527 Total non-convertible notes payable 213,405 800,000 - 1,013,405 5,016 Total convertible and non-convertible 3,589,931 800,000 - 4,389,931 44,556 Notes: (1) On March 17, 2022, we executed a Promissory Note Extension Agreement with Ainos KY in which the due dates for certain convertible notes enumerated as #12.21 to #24.21 issued by the Company to Ainos KY were extended to February 28, 2023. The total unpaid principal for these extended period convertible notes amount to $3,000,000 in the aggregate. (2) On March 11, 2022, the Board approved a Non-Convertible Note dated March 4, 2022 in favor of Ainos KY with a principal amount of $800,000, interest of 1.85% per annum on unpaid principal and accrued interest, and a maturity date of February 28, 2023. The Note includes standard provisions for notice, default, and remedies for default. All of the aforementioned convertible promissory notes and other notes payable are unsecured and due on demand upon maturity. The Company may prepay the notes in whole or in part at any time. The holder of convertible notes has the option to convert some or all of the unpaid principal and accrued interest to our common voting stock. The total interest expense of convertible notes payable and other notes payable for the three months ended March 31, 2022 and as of December 31 2021 was $15,883 and $11,897 respectively; the cumulative related accrued interest as of March 31, 2022 and December 31, 2021 were $44,556 and $28,673, respectively.	4. Convertible Notes Payable and Other Notes Payable All convertible and other notes payable were issued either as a result of financing or deferred compensation provided by executives of the Company. As of December 31, 2021 and December 31, 2020, convertible and other notes payable totaled $3,589,931 and $953,001, respectively; including notes payable for related parties totaling $3,505,931 and $805,001, respectively. Refer to disclosure in Note 5 below. The details of the convertible notes payable and other notes payable are shown in the table below: Payee No. Effective Date Due Date From Effective Following Maturity Conversion Rate Issuing Purpose 1/1/2021 Addition Payment 12/31/2021 Accrued Interest Convertible notes payable: Stephen Chen #1.16 1/30/2016 Payable on demand 0.75% NA $ 0.17 working capital 114,026 114,026 5,839 Stephen Chen #2.16 3/18/2016 Payable on demand 0.65% NA $ 0.19 working capital 262,500 262,500 9,878 Stephen Chen #3.19 912019 9/1/2020 1.85% 10% $ 0.25 salary 39,620 (39,620) 0 0 Stephen Chen #4.19 1212019 12/31/2020 1.61% 10% $ 0.25 working capital 14,879 (14,879) 0 0 Stephen Chen #6.20 112020 1/1/2021 1.85% 10% $ 0.25 salary 216,600 (216,600) 0 0 Stephen Chen #7.20 112020 1/2/2021 1.60% 10% $ 0.25 working capital 23,366 (23,366) 0 0 Stephen Chen #10.21 112021 4/1/2021 1.85% 1.85% $ 0.25 salary 59,025 (59,025) 0 0 Stephen Chen #11.21 412021 5/1/2021 1.85% 10% $ 0.25 salary 10,000 (10,000) 0 0 670,991 69,025 (363,490) 376,526 15,717 Ainos KY #12.21 4/27/2021 10/27/2021 1.85% NA $ 0.20 working capital 15,000 15,000 189 Ainos KY #13.21 5/5/2021 11/5/2021 1.85% NA $ 0.20 working capital 20,000 20,000 243 Ainos KY #14.21 5/25/2021 11/25/2021 1.85% NA $ 0.20 working capital 30,000 30,000 335 Ainos KY #15.21 5/28/2021 11/28/2021 1.85% NA $ 0.20 working capital 35,000 35,000 385 Ainos KY #16.21 6/9/2021 12/9/2021 1.85% NA $ 0.20 working capital 300,000 300,000 3,117 Ainos KY #17.21 6/21/2021 12/21/2021 1.85% NA $ 0.20 working capital 107,000 107,000 1,047 Ainos KY #18.21 7/2/2021 1/2/2022 1.85% NA $ 0.20 working capital 54,000 54,000 498 Ainos KY #19.21 912021 3/1/2022 1.85% NA $ 0.20 working capital 120,000 120,000 742 Ainos KY #20.21 9/28/2021 3/28/2022 1.85% NA $ 0.20 working capital 300,000 300,000 1,429 Ainos KY #21.21 11102021 5102022 1.85% NA $ 0.20 working capital 50,000 50,000 129 Ainos KY #22.21 11252021 11/25/2022 1.85% NA $ 0.20 working capital 450,000 450,000 798 Ainos KY #23.21 11/29/2021 5/29/2022 1.85% NA $ 0.20 working capital 300,000 300,000 471 Ainos KY #24.21 12292021 6/29/2022 1.85% NA $ 0.20 working capital 1,219,000 1,219,000 124 0 3,000,000 0 3,000,000 9,507 Total convertible notes payable- related parties 670,991 3,069,025 (363,490) 3,376,526 25,224 i2 China #5.19 9/1/2019 9/1/2020 1.85% 10% $ 0.25 consulting fee 16,000 (16,000) 0 0 i2 China #8a.20 1/1/2020 1/1/2021 1.85% 10% $ 0.25 consulting fee 48,000 (48,000) 0 0 i2 China #11.21 112020 4/1/2021 1.85% 10% $ 0.25 consulting fee 37,000 (37,000) 0 0 Total convertible notes payable- non-related party 64,000 37,000 (101,000) 0 0 Total Convertible notes payable 734,991 3,106,025 (464,490) 3,376,526 25,224 Notes payable: Stephen Chen #9.21 1/1/2021 4/14/2021 0.13% 10% NA working capital 134,010 145,395 (150,000) 129,405 312 Notes payable-related party 134,010 145,395 (150,000) 129,405 312 i2 China #8b.20 1/1/2020 1/1/2021 1.85% 10% NA consulting fee 84,000 84,000 3,137 Notes payable- non-related party 84,000 0 0 84,000 3,137 Total notes payable 218,010 145,395 (150,000) 213,405 3,449 Total convertible and non-convertible 953,001 3,251,420 (614,490) 3,589,931 28,673 All of the aforementioned convertible promissory notes and other notes payable are unsecured and due on demand upon maturity. The Company may prepay the notes in whole or in part at any time. The Payee has the option to convert some or all of the unpaid principal and accrued interest to our common voting stock. The convertible promissory notes are convertible on demand. The following convertible notes due to Stephen T. Chen - Notes 3.19, 4.19, 6.20, 7.20, 10.21, and 11.21 -- with a total principal and accrued interest amount of $372,988 were assigned by the holder to Top Calibre Corporation, a British Virgin Islands corporation, and subsequently converted in common stock of our company at a conversion price of $0.25 per share on December 27, 2021. No convertible notes were assigned in 2020. During 2021, the Company received funding from Dr. Stephen T. Chen and Ainos KY totaling $214,420 and $3,000,000, respectively. Amounts owed to Dr. Stephen T. Chen of $150,000 were repaid. In 2020, the Company received funding from Dr. Stephen T. Chen totaling $373,976. Note holders, i2China Management Group, LLC (“i2China”) and Dr. Stephen T. Chen (together the “Payees”), agreed to waive their rights pertaining to the conditional term “Annual Interest Rate on Matured, Unpaid Amounts: 10% per annum, compounded annually of Convertible Notes” in regards to interest charged on unpaid amounts following maturity for all of their respective notes. The Company and the Payees agree that the originally agreed annual interest rate will continue to be valid for any unpaid amounts after maturity. The amended terms of the above convertible notes and other notes payable were made during on September 1, 2021. Interest waived totaled $45,875. The total interest expense for 2021 and 2020 totaled $21,727 and $10,702 respectively; the cumulative related accrued interest as of December 31, 2021 and 2020 were $28,673 and $24,196, respectively.

Warrants

Warrants	12 Months Ended
	Dec. 31, 2021
Warrants
Warrants	9. Warrants As of December 31, 2021, there is only one warrant certificate outstanding between the Company and i2China Management Group, LLC, deemed for the purposes of related party transactions to be a related party of the company from August 1, 2021 to December 1, 2021, effective from November 25, 2020 until November 25, 2025. The warrant entitles the holder to purchase 452,617 shares of common stock at an exercise price of $0.27 per share. The warrant was valued at $68,349 and will be expensed over sixty (60) months. The Company used the Black-Scholes option pricing model to value the warrants with the following assumptions applied: (1) Volatility - 201%; (2) Term - 5 years (3) Discount Rate - 0.11%. No warrants were exercised in 2020 or 2021.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2021
Income Taxes
Income Taxes	10. Income Taxes The Company accounts for income taxes under FASB Accounting Standard Codification ASC 740, Income Taxes Income tax expense (benefit) attributable to income from continuing operations differed from the amounts computed by applying the U.S. Federal income tax of 21% to pretax income from continuing operations as a result of the following: December 31, 2021 2020 Provision (benefit) at statutory rate $ (816,000 ) $ (305,000 ) Permanent differences - 1,000 Temporary differences 206,000 79,000 Change in valuation allowance 610,000 225,000 The tax effects of temporary differences that give rise to significant portions of the deferred tax assets and deferred tax liabilities at December 31, 2021 and 2020, are presented below: December 31, 2021 2020 Deferred tax assets: Net operating loss carryforward $ 4,357,000 $ 4,328,270 Other assets 248,000 217,000 Deferred tax assets 4,605,000 4,545,270 Deferred tax liabilities: - - Net deferred tax assets 4,605,000 4,545,270 Valuation allowance (4,605,000 ) (4,545,270 ) At December 31, 2021, we estimate net operating loss carryforwards of approximately $20,747,517 for federal income tax purposes expiring in 2022 through 2041. The ability of the Company to utilize these carryforwards may be difficult and directly dependent upon many factors outside of our control, including, but not limited to, changes in the legal and regulatory framework and the operational and corporate structure of the Company and shareholders, or sales or transfers of stock by or among shareholders. For example, when the Company has experienced a change of control as defined in the relevant provisions of the Internal Revenue Code of 1986, as amended, the use of any existing tax attributes would be severely limited. Also, obtaining value from the tax attributes is a function our return to profitable operations and the timeframe of that return. While we believe it is possible, there is no assurance that the Company will return to profitability in the future. As of December 31, 2021, the Company had open tax years of 2020, 2019 and 2018 which are subject to examination by tax authorities.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2021
Commitments and Contingencies
Commitments And Contingencies	11. Commitments and Contingencies Lease and contract commitment Our executive and administrative offices in the U.S. are located at 8880 Rio San Diego Drive, Suite 800, San Diego, CA 92108. The lease term began on April 1, 2021 as a semi-annual term and automatically renewed currently as a month-to-month renewal agreement. Our Taiwan branch office is located in New Taipei City, Taiwan (“R.O.C.”) under a three-year office lease contract from June 2021 to May 2024. The office space is 1,250 square feet. We also have staff at a product development facility of approximately 8,517 square feet located in Miaoli County, Taiwan, pursuant to our Product Development Agreement with TCNT. We have several construction work related contracts to build out our office and lab facilities in Taiwan. As of December 31, 2021, the total contract amount and outstanding contract amount for construction in progress were approximately US$670,000 and US$464,000, respectively. Litigation We not at this time involved in any legal proceedings. Officer Compensation Effective April 15, 2021, our Board appointed Mr. Chun-Hsien Tsai to serve as Chief Executive Officer. Mr. Tsai will receive a monthly salary of 250,000 New Taiwan Dollars (equivalent to approximately $8,929), a year-end bonus of two months’ salary, and a variable compensation based on Company profit targets decided by the Company’s Compensation Committee, and payable as 10-30% of total annual compensation in the form of cash, securities and/or other discretionary remuneration. An initial equity grant to Mr. Tsai will be determined by the Compensation Committee at a later date. Other benefits, including labor insurance, health insurance and other benefits, will be based on local regulations and the Company’s policies. Effective August 11, 2021, our Board appointed Ms. Hui-Lan (“Celia”) Wu to serve as Chief Financial Officer. Ms. Wu will receive a monthly salary of 230,000 New Taiwan Dollars (equivalent to approximately $8,214), a year-end bonus of 2 months’ salary, and a variable compensation based on Company profit targets decided by the Company’s Compensation Committee, and payable as 10-30% of total annual compensation in the form of cash, securities and/or other discretionary remuneration. An initial equity grant to Ms. Wu will be determined by the Compensation Committee at a later date. Other benefits, including labor insurance, health insurance and other benefits, will be based on local regulations and the Company’s policies. Effective August 1, 2021, we entered into an employment contract with Mr. Lawrence K. Lin in connection with his election as Executive Vice President of Operations (the “LL Agreement”). The LL Agreement is effective for three years and may be extended for additional years on the same terms and conditions upon mutual agreement. Under the LL Agreement, Mr. Lin will receive a monthly salary of $12,000, vesting stock options for 500,000 shares in the Company’s 2018 Officers, Directors, Employees and Consultants Non-Qualified Stock Option Plan, and a bonus of 10,000 shares in the Company’s common stock upon the Company’s successful listing on a Major National Exchange (as defined in the LL Agreement), and normal and customary benefits available to the Company’s employees. Mr. Lin is the sole member of i2China Management Group, LLC (“i2China”), a consultant previously engaged by the Company. Mr. Lin indirectly owns 452,617 warrants issued on November 25, 2020 to i2China; a non-convertible note issued to i2China on January 1, 2020 with a principal amount of $84,000; and convertible notes issued to i2China with a total principal and accrued interest amount of $103,342, that were converted into 413,368 shares of common stock on December 27, 2021 at a conversion price of $0.25 per share. We previously hired Dr. Stephen T. Chen under an employment contract for the period January 1, 2018 through December 31, 2020 (“Prior Chen Contract”). On January 1, 2021 an employment agreement for a 3-month term was executed reflecting the same material terms and conditions of the Prior Chen Contract which includes (i) a $240,000 annual salary, (ii) $100,000 in Company shares payable quarterly based on the average share price of the closing quotes for the one month preceding issuance (referred to in the table as “Other Compensation”), (iii) certain employee benefits available to the our employees, and (iv) reimbursement of expenses made on behalf of the Company. The Company and Dr. Chen also executed a Settlement Agreement and Mutual General Release made effective December 24, 2020 covering any employment-related claims arising under the Prior Chen Contract. The Company and Dr. Chen also entered into an Intellectual Property Assignment Agreement made effective January 19, 2021 whereby Dr. Chen has assigned all right, title, and interest to certain patents, trademarks, and other intellectual property created or developed during Dr. Chen’s employment with the Company. We previously hired Mr. Cohen under an employment contract for the period January 1, 2018 through December 31, 2020 (“Prior Cohen Contract”). On January 1, 2021 an employment agreement for a 3-month term was executed reflecting the same material terms and conditions of the Prior Cohen Contract which includes, (i) a $70,000 annual salary, (ii) $1,000 per month in Company shares paid monthly based on the average share price of the closing quotes for the one month preceding issuance (referred to in the table as “Other Compensation”), (iii) certain employee benefits available to the Company’s employees, and (iv) reimbursement of expenses made on behalf of the Company. The Company and Mr. Cohen also executed a Settlement Agreement and Mutual General Release made effective December 24, 2020 covering any employment-related claims arising under the Prior Cohen Contract. The Company and Mr. Cohen also entered into an Intellectual Property Assignment Agreement made effective January 19, 2021 whereby Mr. Cohen has assigned all right, title, and interest to certain patents, trademarks, and other intellectual property created or developed during Mr. Cohen’s employment with the Company.

Subsequent Events

Subsequent Events	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Subsequent Events
Subsequent Events	9. Subsequent Events. On April 11, 2022, we issued to ASE Test Inc., a minority owner of Ainos KY, a convertible note in the principal amount of $500,000 due on March 30, 2027 (the “ASE Note”). The convertible note will automatically convert into shares of our common stock immediately prior to the closing of any public offering of our common stock as a result of which our common stock will be listed on a U.S. stock exchange. The conversion price, subject to certain adjustments, will be 80% of the initial public offering price of the offering.	12. Subsequent Events Asset Purchase Agreement Ainos KY and the Company entered into an Asset Purchase Agreement dated as of November 18, 2021 as modified by an Amended and Restated Asset Purchase Agreement dated as of January 29, 2022 (the “Asset Purchase Agreement”). Pursuant to the Asset Purchase Agreement, the Company acquired certain intellectual property assets (the “IP Assets”) and certain manufacturing, testing, and office equipment (the “Equipment”) for a total purchase price of $26,000,000. Pursuant to the Asset Purchase Agreement, the Company agreed to hire certain employees of Ainos KY (the “Employees”) who are responsible for research and development of the IP Assets and/or Equipment on terms at least equal to the compensation arrangements undertaken by Ainos KY. From and after the closing, we will have no responsibility, duty or liability with respect to any employee benefit plans of Ainos KY. As payment of the purchase price, we issued to Ainos KY a Convertible Promissory Note in the principal amount of $26,000,000 (the “Convertible Note”) upon closing on January 30, 2022. The principal sum of the Convertible Note is payable in cash on January 30, 2027, although we may prepay the Convertible Note in whole or in part without penalty. The Convertible Note is noninterest bearing. If not earlier repaid, the Convertible Note will be converted into shares of our common stock or such other securities or property for which the Convertible Note may become convertible, immediately prior to the closing of any public offering of our common stock as a result of which our common stock will be listed on a U.S. stock exchange. The conversion price, subject to certain adjustments, will be 80% of the initial public offering price of the offering. On March 11, 2022, the Board approved a Non-Convertible Note dated March 4, 2022 in favor of Ainos KY with a principal amount of $800,000, interest of 1.85% per annum on unpaid principal and accrued interest, and a maturity date of February 28, 2023. The Note includes standard provisions for notice, default, and remedies for default. Ainos KY is the Company’s majority and controlling shareholder. On March 17, 2022, we executed a Promissory Note Extension with Ainos KY dated March 17, 2022. Pursuant to the Agreement, the due dates for certain convertible notes enumerated as #12.21 to #24.21 issued by the Company to Ainos KY was extended to February 28, 2023. As of December 31, 2021 the total unpaid principal amount of $3,000,000, along with $9,507 in accrued interest were owed and outstanding to Ainos KY.

Organization and Summary of S_2

Organization and Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2021
Organization and Summary of Significant Accounting Policies
Organization And Business	We are engaged in developing medical technologies for point-of-care (“POCT”) testing and safe and novel medical treatment for a broad range of disease indications. Since our inception in 1984, we have concentrated our resources on business planning, raising capital, research and clinical development activities for our programs, securing related intellectual property and commercialization of proprietary therapeutics using low-dose non-injectable interferon (“IFN”). In addition to our core IFN technology, we are committed to developing a diversified healthcare business portfolio to include medical devices and consumer healthcare products. Although we have historically been involved in extensive pharmaceutical research and development of low-dose oral interferon as a therapeutic, we are prioritizing the commercialization of medical devices as part of our diversification strategy. Since the beginning of 2021, we have acquired significant intellectual property from our majority shareholder, Ainos KY, to expand our potential product portfolio into Volatile Organic Compounds (“VOC”) and COVID-19 POCTs. This includes 51 issued and pending patents related to VOC technologies and 3 issued patents for COVID-19 POCT products. We expect our underlying intellectual property to enable us to expedite the commercialization of our medical device pipeline, beginning with Ainos-branded COVID-19 POCT product candidates.
Basis Of Accounting	The basis is United States generally accepted accounting policies (“U.S. GAAP”).
Fair Value Of Financial Instruments	Under the Financial Account Standards Board Accounting Standards Codification (“FASB ASC”), we are permitted to elect to measure financial instruments and certain other items at fair value, with the change in fair value recorded in earnings. We elected not to measure any eligible items using the fair value option. Consistent with the Fair Value Measurement Topic of the FASB ASC, we implemented guidelines relating to the disclosure of our methodology for periodic measurement of our assets and liabilities recorded at fair market value. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. A three-tier fair value hierarchy prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurements) and the lowest priority to unobservable inputs (level 3 measurements). These tiers include: · Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets; · Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and · Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one more significant inputs or significant value drivers are unobservable. Our Level 1 assets and liabilities primarily include our cash and cash equivalents. Valuations are obtained from readily available pricing sources for market transactions involving identical assets or liabilities. The carrying amounts of accounts receivable, prepaid expense, accounts payable, accrued liabilities, advances from investors, and notes payable approximate fair value due to the immediate or short-term maturities of these financial instruments.
Going Concern	These financial statements have been prepared in accordance with United States generally accepted accounting principles (“U.S. GAAP”) applicable to a going concern, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. The Company has generated minimal revenue and has an accumulated deficit totaling $10,108,916 since inception. These factors, among others, indicate that there is substantial doubt about the Company’s ability to continue as a going concern within one year from the issuance date of this filing. In order to obtain the necessary capital to sustain operations, management’s plans include, among other things, the possibility of pursuing new equity sales and/or making additional debt borrowings, There can be no assurances, however, that the Company will be successful in obtaining additional financing, or that such financing will be available on favorable term, if at all. Obtaining commercial loans, assuming those loans would be available, will increase the Company’s liabilities and future cash commitments. If the Company is unable to obtain financing in the amounts and on terms deemed acceptable, the business and future success may be adversely affected and the Company may cease operations. These factors raise substantial doubt regarding our ability to continue as a going concern. The accompanying financial statements do not include any adjustments relative to the recoverability and classification of asset carrying amounts or the amount and classification of liabilities that might result from the outcome of this uncertainty.
Stock-based Compensation	Stock-based compensation expense is recorded in accordance with FASB ASC Topic 718, Compensation - Stock Compensation
Cash And Cash Equivalents	The Company classifies investments as cash equivalents if the original maturity of an investment is three months or less.
Revenue Recognition	We account for revenue from contracts with customers in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Update (“ASU”) No. 2014-09, “Revenue from Contracts with Customers (“Topic 606”).” The unit of account in Topic 606 is a performance obligation, which is a promise in a contract to transfer to a customer either a distinct good or service (or bundle of goods or services) or a series of distinct goods or services provided at a point in time or over a period of time. Topic 606 requires that a contract’s transaction price, which is the amount of consideration to which an entity expects to be entitled in exchange for transferring promised goods or services to a customer, is to be allocated to each performance obligation in the contract based on relative standalone selling prices and recognized as revenue when (point in time) or as (over time) the performance obligation is satisfied. Total revenues include sales of products to customers, net of discounts or allowances, if any, and include freight and delivery costs billed to customers. Revenues for product sales are recognized when control of the promised good is transferred to unaffiliated customers, typically when finished products are shipped. Shipping costs are deemed fulfillment costs and are not recognized as a separate performance obligation.
Allowance For Doubtful Accounts	The Company establishes an allowance for doubtful accounts to ensure trade and notes receivable are not overstated due to non-collectability. The Company’s allowance is based on a variety of factors, including age of the receivable, significant one-time events, historical experience, and other risk considerations. The Company had no material accounts receivable and no allowance at December 31, 2021 or 2020.
Inventory	Inventories are stated at the lower of cost or market. Cost is determined on a first-in, first-out basis. The Company continually assesses the appropriateness of inventory valuations giving consideration to slow-moving, non-saleable, out-of-date or close-dated inventory.
Property And Equipment	Property and equipment are stated on the basis of historical cost less accumulated depreciation. Depreciation is provided using the straight-line method over the two to seven year estimated useful lives of the assets.
Patents And Patent Expenditures	The Company holds patent license agreements and maintains patents that are owned by the Company. All patent license agreements remain in effect over the life of the underlying patents. Accordingly, the patent license fee is being amortized over the estimated life of the patent using the straight-line method. Patent fees and legal fees associated with the issuance of new owned patents are capitalized and amortized over the estimated 8 to 20 year life of the patent. The Company continually evaluates the amortization period and carrying basis of patents to determine whether subsequent events and circumstances warrant a revised estimated useful life or impairment in value. No patent costs were written off for the years ended December 31, 2021, or December 31, 2020.
Income Taxes	The asset and liability approach is used to account for income taxes by recognizing deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the carrying amounts and the tax bases of assets and liabilities. The Company records a valuation allowance to reduce the deferred tax assets to the amount that is more likely than not to be realized.
Research And Development	Internal research and development (“R&D”) costs are expensed as incurred. Clinical trial costs incurred by third parties are expensed as the contracted work is performed. Where contingent milestone payments are due to third parties under research and development collaborations, prior to regulatory approval, the payment obligations are expensed when the milestone results are achieved. Payments made to third parties subsequent to regulatory approval are capitalized as intangible assets and amortized to cost of products sold over the remaining useful life of the related product.
Use Of Estimates	The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Basic And Diluted Net Income (loss) Per Share	The basic earnings (loss) per share is calculated by dividing the Company’s net income (loss) available to common shareholders by the weighted average number of common shares issued and outstanding during the year. The diluted earnings (loss) per share is calculated by dividing the Company’s net income (loss) available to common shareholders by the diluted weighted average number of shares outstanding during the year. The diluted weighted average number of shares outstanding is the basic weighted number of shares adjusted as of the first year for any potentially dilutive debt or equity. As of December 31, 2021, potentially dilutive shares are not included in the calculation of fully diluted net loss per share as the effect with a net loss would be antidilutive.
Concentration Of Credit Risk	Financial instruments that potentially subject the Company to significant concentration of credit risk consist principally of cash. The Company has cash balances in a single U.S. financial institution which, from time to time, could exceed the federally insured limit of $250,000. The Company maintains multiple accounts in its Taiwan Branch office which help to mitigate risk. Our bank deposits in Taiwan are insured by the Central Deposit Insurance Corp. (“CDIC”) with an insured limit of NT$3,000,000 per account. No loss has been incurred related to the aforementioned concentration of cash.
Recent Accounting Pronouncements	There have been no new accounting pronouncements issued or adopted during the year ended December 31, 2021 that are of significance to us.

Property, Equipment and Softwar

Property, Equipment and Software, net (Tables)	12 Months Ended
	Dec. 31, 2021
Property, Equipment, net
Property, Equipment And Software	December 31, 2021 2020 Machinery and equipment $ 938,047 $ - Furniture and fixture 47,960 107,549 Construction in process 232,729 - Total cost 1,218,736 107,549 Less: accumulated depreciation (31,034 ) (104,300 ) Property and equipment, net $ 1,187,702 $ 3,249

Patents, net (Tables)

Patents, net (Tables)	12 Months Ended
	Dec. 31, 2021
Patents, net
Patents	December 31, 2021 2020 Patents and technology $ 39,371,317 $ 245,898 Less: accumulated amortization (2,042,126 ) (65,270 ) Patents and technology, net $ 37,329,191 $ 180,628
Estimated Future Amortization Expense	2022 4,522,141 2023 4,522,141 2024 4,534,493 2025 4,522,141 2026 4,521,973 Thereafter 14,706,301 Total expense $ 37,329,191

Convertible Notes Payable (Tabl

Convertible Notes Payable (Tables)	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Convertible Notes Payable
Convertible Notes Payable	Payee No. Effective Date Due Date From Effective Following Maturity Conversion Rate Issuing Purpose As of 12/31/2021 Addition Payment As of 3/31/2022 Accrued Interest Current Convertible Notes Payable: Stephen Chen #1.16 1/30/2016 Payable on demand 0.75% N/A $ 0.17 working capital 114,026 - - 114,026 6,050 Stephen Chen #2.16 3/18/2016 Payable on demand 0.65% N/A $ 0.19 working capital 262,500 - - 262,500 10,298 376,526 - - 376,526 16,348 Ainos KY #12.21 4/27/2021 2/28/2023 (1) 1.85% N/A $ 0.20 working capital 15,000 - - 15,000 257 Ainos KY #13.21 5/5/2021 2/28/2023 (1) 1.85% N/A $ 0.20 working capital 20,000 - - 20,000 335 Ainos KY #14.21 5/25/2021 2/28/2023 (1) 1.85% N/A $ 0.20 working capital 30,000 - - 30,000 471 Ainos KY #15.21 5/28/2021 2/28/2023 (1) 1.85% N/A $ 0.20 working capital 35,000 - - 35,000 545 Ainos KY #16.21 6/9/2021 2/28/2023 (1) 1.85% N/A $ 0.20 working capital 300,000 - - 300,000 4,486 Ainos KY #17.21 6/21/2021 2/28/2023 (1) 1.85% N/A $ 0.20 working capital 107,000 - - 107,000 1,535 Ainos KY #18.21 7/2/2021 2/28/2023 (1) 1.85% N/A $ 0.20 working capital 54,000 - - 54,000 744 Ainos KY #19.21 9/1/2021 2/28/2023 (1) 1.85% N/A $ 0.20 working capital 120,000 - - 120,000 1,289 Ainos KY #20.21 9/28/2021 2/28/2023 (1) 1.85% N/A $ 0.20 working capital 300,000 - - 300,000 2,798 Ainos KY #21.21 11/10/2021 2/28/2023 (1) 1.85% N/A $ 0.20 working capital 50,000 - - 50,000 357 Ainos KY #22.21 11/25/2021 2/28/2023 (1) 1.85% N/A $ 0.20 working capital 450,000 - - 450,000 2,851 Ainos KY #23.21 11/29/2021 2/28/2023 (1) 1.85% N/A $ 0.20 working capital 300,000 - - 300,000 1,840 Ainos KY #24.21 12/29/2021 2/28/2023 (1) 1.85% N/A $ 0.20 working capital 1,219,000 - - 1,219,000 5,684 3,000,000 - - 3,000,000 23,192 Total convertible notes payable- related parties 3,376,526 - - 3,376,526 39,540 Non-Convertible Notes Payable: Stephen Chen #9.21 1/1/2021 4/14/2021 0.13% N/A N/A working capital 129,405 - - 129,405 354 Ainos KY #26.22 (2) 3/4/2022 3/31/2023 1.85% N/A N/A working capital - 800,000 - 800,000 1,135 Non-convertible notes payable-related party 129,405 800,000 - 929,405 1,489 i2 China #8b.20 1/1/2020 1/1/2021 1.85% N/A N/A consulting fee 84,000 - - 84,000 3,527 Non-Convertible Notes payable- non-related party 84,000 84,000 3,527 Total non-convertible notes payable 213,405 800,000 - 1,013,405 5,016 Total convertible and non-convertible 3,589,931 800,000 - 4,389,931 44,556	Payee No. Effective Date Due Date From Effective Following Maturity Conversion Rate Issuing Purpose 1/1/2021 Addition Payment 12/31/2021 Accrued Interest Convertible notes payable: Stephen Chen #1.16 1/30/2016 Payable on demand 0.75% NA $ 0.17 working capital 114,026 114,026 5,839 Stephen Chen #2.16 3/18/2016 Payable on demand 0.65% NA $ 0.19 working capital 262,500 262,500 9,878 Stephen Chen #3.19 912019 9/1/2020 1.85% 10% $ 0.25 salary 39,620 (39,620) 0 0 Stephen Chen #4.19 1212019 12/31/2020 1.61% 10% $ 0.25 working capital 14,879 (14,879) 0 0 Stephen Chen #6.20 112020 1/1/2021 1.85% 10% $ 0.25 salary 216,600 (216,600) 0 0 Stephen Chen #7.20 112020 1/2/2021 1.60% 10% $ 0.25 working capital 23,366 (23,366) 0 0 Stephen Chen #10.21 112021 4/1/2021 1.85% 1.85% $ 0.25 salary 59,025 (59,025) 0 0 Stephen Chen #11.21 412021 5/1/2021 1.85% 10% $ 0.25 salary 10,000 (10,000) 0 0 670,991 69,025 (363,490) 376,526 15,717 Ainos KY #12.21 4/27/2021 10/27/2021 1.85% NA $ 0.20 working capital 15,000 15,000 189 Ainos KY #13.21 5/5/2021 11/5/2021 1.85% NA $ 0.20 working capital 20,000 20,000 243 Ainos KY #14.21 5/25/2021 11/25/2021 1.85% NA $ 0.20 working capital 30,000 30,000 335 Ainos KY #15.21 5/28/2021 11/28/2021 1.85% NA $ 0.20 working capital 35,000 35,000 385 Ainos KY #16.21 6/9/2021 12/9/2021 1.85% NA $ 0.20 working capital 300,000 300,000 3,117 Ainos KY #17.21 6/21/2021 12/21/2021 1.85% NA $ 0.20 working capital 107,000 107,000 1,047 Ainos KY #18.21 7/2/2021 1/2/2022 1.85% NA $ 0.20 working capital 54,000 54,000 498 Ainos KY #19.21 912021 3/1/2022 1.85% NA $ 0.20 working capital 120,000 120,000 742 Ainos KY #20.21 9/28/2021 3/28/2022 1.85% NA $ 0.20 working capital 300,000 300,000 1,429 Ainos KY #21.21 11102021 5102022 1.85% NA $ 0.20 working capital 50,000 50,000 129 Ainos KY #22.21 11252021 11/25/2022 1.85% NA $ 0.20 working capital 450,000 450,000 798 Ainos KY #23.21 11/29/2021 5/29/2022 1.85% NA $ 0.20 working capital 300,000 300,000 471 Ainos KY #24.21 12292021 6/29/2022 1.85% NA $ 0.20 working capital 1,219,000 1,219,000 124 0 3,000,000 0 3,000,000 9,507 Total convertible notes payable- related parties 670,991 3,069,025 (363,490) 3,376,526 25,224 i2 China #5.19 9/1/2019 9/1/2020 1.85% 10% $ 0.25 consulting fee 16,000 (16,000) 0 0 i2 China #8a.20 1/1/2020 1/1/2021 1.85% 10% $ 0.25 consulting fee 48,000 (48,000) 0 0 i2 China #11.21 112020 4/1/2021 1.85% 10% $ 0.25 consulting fee 37,000 (37,000) 0 0 Total convertible notes payable- non-related party 64,000 37,000 (101,000) 0 0 Total Convertible notes payable 734,991 3,106,025 (464,490) 3,376,526 25,224 Notes payable: Stephen Chen #9.21 1/1/2021 4/14/2021 0.13% 10% NA working capital 134,010 145,395 (150,000) 129,405 312 Notes payable-related party 134,010 145,395 (150,000) 129,405 312 i2 China #8b.20 1/1/2020 1/1/2021 1.85% 10% NA consulting fee 84,000 84,000 3,137 Notes payable- non-related party 84,000 0 0 84,000 3,137 Total notes payable 218,010 145,395 (150,000) 213,405 3,449 Total convertible and non-convertible 953,001 3,251,420 (614,490) 3,589,931 28,673

Current Convertible Notes Pay_2

Current Convertible Notes Payable and Other Notes Payable (Table)	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Convertible Notes Payable
Convertible Notes Payable	Payee No. Effective Date Due Date From Effective Following Maturity Conversion Rate Issuing Purpose As of 12/31/2021 Addition Payment As of 3/31/2022 Accrued Interest Current Convertible Notes Payable: Stephen Chen #1.16 1/30/2016 Payable on demand 0.75% N/A $ 0.17 working capital 114,026 - - 114,026 6,050 Stephen Chen #2.16 3/18/2016 Payable on demand 0.65% N/A $ 0.19 working capital 262,500 - - 262,500 10,298 376,526 - - 376,526 16,348 Ainos KY #12.21 4/27/2021 2/28/2023 (1) 1.85% N/A $ 0.20 working capital 15,000 - - 15,000 257 Ainos KY #13.21 5/5/2021 2/28/2023 (1) 1.85% N/A $ 0.20 working capital 20,000 - - 20,000 335 Ainos KY #14.21 5/25/2021 2/28/2023 (1) 1.85% N/A $ 0.20 working capital 30,000 - - 30,000 471 Ainos KY #15.21 5/28/2021 2/28/2023 (1) 1.85% N/A $ 0.20 working capital 35,000 - - 35,000 545 Ainos KY #16.21 6/9/2021 2/28/2023 (1) 1.85% N/A $ 0.20 working capital 300,000 - - 300,000 4,486 Ainos KY #17.21 6/21/2021 2/28/2023 (1) 1.85% N/A $ 0.20 working capital 107,000 - - 107,000 1,535 Ainos KY #18.21 7/2/2021 2/28/2023 (1) 1.85% N/A $ 0.20 working capital 54,000 - - 54,000 744 Ainos KY #19.21 9/1/2021 2/28/2023 (1) 1.85% N/A $ 0.20 working capital 120,000 - - 120,000 1,289 Ainos KY #20.21 9/28/2021 2/28/2023 (1) 1.85% N/A $ 0.20 working capital 300,000 - - 300,000 2,798 Ainos KY #21.21 11/10/2021 2/28/2023 (1) 1.85% N/A $ 0.20 working capital 50,000 - - 50,000 357 Ainos KY #22.21 11/25/2021 2/28/2023 (1) 1.85% N/A $ 0.20 working capital 450,000 - - 450,000 2,851 Ainos KY #23.21 11/29/2021 2/28/2023 (1) 1.85% N/A $ 0.20 working capital 300,000 - - 300,000 1,840 Ainos KY #24.21 12/29/2021 2/28/2023 (1) 1.85% N/A $ 0.20 working capital 1,219,000 - - 1,219,000 5,684 3,000,000 - - 3,000,000 23,192 Total convertible notes payable- related parties 3,376,526 - - 3,376,526 39,540 Non-Convertible Notes Payable: Stephen Chen #9.21 1/1/2021 4/14/2021 0.13% N/A N/A working capital 129,405 - - 129,405 354 Ainos KY #26.22 (2) 3/4/2022 3/31/2023 1.85% N/A N/A working capital - 800,000 - 800,000 1,135 Non-convertible notes payable-related party 129,405 800,000 - 929,405 1,489 i2 China #8b.20 1/1/2020 1/1/2021 1.85% N/A N/A consulting fee 84,000 - - 84,000 3,527 Non-Convertible Notes payable- non-related party 84,000 84,000 3,527 Total non-convertible notes payable 213,405 800,000 - 1,013,405 5,016 Total convertible and non-convertible 3,589,931 800,000 - 4,389,931 44,556	Payee No. Effective Date Due Date From Effective Following Maturity Conversion Rate Issuing Purpose 1/1/2021 Addition Payment 12/31/2021 Accrued Interest Convertible notes payable: Stephen Chen #1.16 1/30/2016 Payable on demand 0.75% NA $ 0.17 working capital 114,026 114,026 5,839 Stephen Chen #2.16 3/18/2016 Payable on demand 0.65% NA $ 0.19 working capital 262,500 262,500 9,878 Stephen Chen #3.19 912019 9/1/2020 1.85% 10% $ 0.25 salary 39,620 (39,620) 0 0 Stephen Chen #4.19 1212019 12/31/2020 1.61% 10% $ 0.25 working capital 14,879 (14,879) 0 0 Stephen Chen #6.20 112020 1/1/2021 1.85% 10% $ 0.25 salary 216,600 (216,600) 0 0 Stephen Chen #7.20 112020 1/2/2021 1.60% 10% $ 0.25 working capital 23,366 (23,366) 0 0 Stephen Chen #10.21 112021 4/1/2021 1.85% 1.85% $ 0.25 salary 59,025 (59,025) 0 0 Stephen Chen #11.21 412021 5/1/2021 1.85% 10% $ 0.25 salary 10,000 (10,000) 0 0 670,991 69,025 (363,490) 376,526 15,717 Ainos KY #12.21 4/27/2021 10/27/2021 1.85% NA $ 0.20 working capital 15,000 15,000 189 Ainos KY #13.21 5/5/2021 11/5/2021 1.85% NA $ 0.20 working capital 20,000 20,000 243 Ainos KY #14.21 5/25/2021 11/25/2021 1.85% NA $ 0.20 working capital 30,000 30,000 335 Ainos KY #15.21 5/28/2021 11/28/2021 1.85% NA $ 0.20 working capital 35,000 35,000 385 Ainos KY #16.21 6/9/2021 12/9/2021 1.85% NA $ 0.20 working capital 300,000 300,000 3,117 Ainos KY #17.21 6/21/2021 12/21/2021 1.85% NA $ 0.20 working capital 107,000 107,000 1,047 Ainos KY #18.21 7/2/2021 1/2/2022 1.85% NA $ 0.20 working capital 54,000 54,000 498 Ainos KY #19.21 912021 3/1/2022 1.85% NA $ 0.20 working capital 120,000 120,000 742 Ainos KY #20.21 9/28/2021 3/28/2022 1.85% NA $ 0.20 working capital 300,000 300,000 1,429 Ainos KY #21.21 11102021 5102022 1.85% NA $ 0.20 working capital 50,000 50,000 129 Ainos KY #22.21 11252021 11/25/2022 1.85% NA $ 0.20 working capital 450,000 450,000 798 Ainos KY #23.21 11/29/2021 5/29/2022 1.85% NA $ 0.20 working capital 300,000 300,000 471 Ainos KY #24.21 12292021 6/29/2022 1.85% NA $ 0.20 working capital 1,219,000 1,219,000 124 0 3,000,000 0 3,000,000 9,507 Total convertible notes payable- related parties 670,991 3,069,025 (363,490) 3,376,526 25,224 i2 China #5.19 9/1/2019 9/1/2020 1.85% 10% $ 0.25 consulting fee 16,000 (16,000) 0 0 i2 China #8a.20 1/1/2020 1/1/2021 1.85% 10% $ 0.25 consulting fee 48,000 (48,000) 0 0 i2 China #11.21 112020 4/1/2021 1.85% 10% $ 0.25 consulting fee 37,000 (37,000) 0 0 Total convertible notes payable- non-related party 64,000 37,000 (101,000) 0 0 Total Convertible notes payable 734,991 3,106,025 (464,490) 3,376,526 25,224 Notes payable: Stephen Chen #9.21 1/1/2021 4/14/2021 0.13% 10% NA working capital 134,010 145,395 (150,000) 129,405 312 Notes payable-related party 134,010 145,395 (150,000) 129,405 312 i2 China #8b.20 1/1/2020 1/1/2021 1.85% 10% NA consulting fee 84,000 84,000 3,137 Notes payable- non-related party 84,000 0 0 84,000 3,137 Total notes payable 218,010 145,395 (150,000) 213,405 3,449 Total convertible and non-convertible 953,001 3,251,420 (614,490) 3,589,931 28,673

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2021
Income Taxes
Deferred Tax Assets And Liabilities	December 31, 2021 2020 Provision (benefit) at statutory rate $ (816,000 ) $ (305,000 ) Permanent differences - 1,000 Temporary differences 206,000 79,000 Change in valuation allowance 610,000 225,000 December 31, 2021 2020 Deferred tax assets: Net operating loss carryforward $ 4,357,000 $ 4,328,270 Other assets 248,000 217,000 Deferred tax assets 4,605,000 4,545,270 Deferred tax liabilities: - - Net deferred tax assets 4,605,000 4,545,270 Valuation allowance (4,605,000 ) (4,545,270 )

Stock Option and Stock Plans (T

Stock Option and Stock Plans (Tables)	12 Months Ended
	Dec. 31, 2021
Stock Option and Stock Plans
Equity Compensation Plan Information	Stock Plans 1 Issue Date Range Total Options Authorized Options Issued Options Remaining 2 2018 Employee Stock Option Plan 3, 4 9/26/18 - 9/26/28 1,000,000 950,000 0 2018 Officers, Directors, Employees, and Consultants Nonqualified Stock Option Plan 3 9/26/18 - 9/26/28 4,000,000 4,495,000 5 0 Date Number of Options 1 Number of Options Nonqualified Weighted Average Exercise Price Weighted Average Remaining Contractual Term Aggregate Intrinsic Value Balance December 31, 2019 850,000 3,807,000 $ 0.38 8 years - Exercised - - - - - Expired or Forfeited - - - - - Balance December 31, 2020 850,000 3,807,000 $ 0.38 7 years Granted 2021 - 500,000 $ 0.38 10 years Exercised 20,000 150,400 $ 0.38 - - Expired or Forfeited 780,000 3,656,600 $ 0.38 - - Balance December 31, 2021 50,000 500,000 $ 0.38 9.54 years - Vested as of December 31, 2021 30,000 0 $ 0.38 6.74 years -

Related Party Transactions (Tab

Related Party Transactions (Tables)	12 Months Ended
	Dec. 31, 2021
Related Party Transactions
Schedule Of List Of Related Parties	Name of the related party Relationship Description Taiwan Carbon Nano Technology Corporation (“TCNT”) Affiliated company TCNT is the majority shareholder of Ainos KY Ainos, Inc. (Cayman Island) (“Ainos KY”) Affiliated company Ainos KY is the majority shareholder of the Company ASE Technology Holding Affiliated company Sole owner of ASE Test Inc. which is Ainos KY’s board member and has more than 10% of the voting rights in Ainos KY Dr. Stephen T. Chen Ainos’ former Chairman, President, CEO and CFO Shareholder with more than 5% of the Company voting rights in 2021 and 2020

Organization and Summary of S_3

Organization and Summary of Significant Accounting Policies (Details Narrative)	12 Months Ended
	Dec. 31, 2021 USD ($)
Recurring Losses	$ 10,108,916
Exceed Federally Insured Limit	250,000
Insured Limit, Per Account	$ 3,000,000
Upper [Member]
Finite Lived Intangible Asset Use Ful Life	20 years
Lower [Member]
Finite Lived Intangible Asset Use Ful Life	8 years

Property and Equipment, net (De

Property and Equipment, net (Details) - USD ($)	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Property, Equipment, Gross		$ 1,218,736	$ 107,549
Less: Accumulated Depreciation		(31,034)	(104,300)
Property, Equipment, Net	$ 1,419,584	1,187,702	3,249
Furniture and Equipment [Member]
Property, Equipment, Gross		47,960	107,549
Machinery and Equipment [Member]
Property, Equipment, Gross		938,047	0
Construction in Progress [Member]
Property, Equipment, Gross		$ 232,729	$ 0

Property and Equipment, net (_2

Property and Equipment, net (Details Narrative) - USD ($)	1 Months Ended	12 Months Ended
	Nov. 30, 2021	Dec. 31, 2021	Dec. 31, 2020	Mar. 31, 2022
Property, Equipment, net
Depreciation Expense		$ 31,395	$ 1,820
Property, Equipment, Net		$ 1,187,702	$ 3,249	$ 1,419,584
Acquired Of Machinery And Equipment From Ainos Ky Pursuant	$ 944,152

Patents net (Details)

Patents net (Details) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Patents, net
Patents	$ 39,371,317	$ 245,898
Less: Accumulated Amortization	(2,042,126)	(65,270)
Patents, Net	$ 37,329,191	$ 180,628

Patents net (Details 1)

Patents net (Details 1) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Patents, net
2022	$ 4,522,141
2023	4,522,141
2024	4,534,493
2025	4,522,141
2026	4,521,973
Thereafter	14,706,301
Total Expense	$ 37,329,191	$ 180,628

Patents net (Details Narrative)

Patents net (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Amortization Expense	$ 2,000,302	$ 12,878
Total Expense	37,329,191	180,628
Patents [Member]
Total Expense	$ 37,329,191	$ 180,628

Convertible Notes Payable and O

Convertible Notes Payable and Oayable (Details) - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Total Convertible And Non-convertible	$ 4,389,931	$ 3,589,931	$ 953,001
Total Convertible And Non-convertible Addition	800,000	3,251,420
Total Convertible And Non-convertible Payment	0	614,490
Total Convertible And Non-convertible Accrued	44,556	28,673
Accrued Interest		28,673	24,196
Accrued Interest		9,507
12.21 [Member] | Ainos KY [Member]
Accrued Interest	$ 257	$ 189
Due Date	02/28/2023	10/27/2021
Annual Interest Rate, From Effective	1.85%	1.85%
Effective Date	4/27/2021	4/27/2021
Unpaid Principal Balance	$ 15,000	$ 15,000	15,000
Conversion Rate	$ 0.20	$ 0.20
Addition	$ 0	$ 15,000
13.21 [Member] | Ainos KY [Member]
Accrued Interest	$ 335	$ 243
Due Date	02/28/2023
Annual Interest Rate, From Effective	1.85%	1.85%
Effective Date	5/5/2021	5/5/2021
Unpaid Principal Balance	$ 20,000	$ 20,000
Conversion Rate	$ 0.20	$ 0.20
Addition		$ 20,000
Due Date		11/5/2021
14.21 [Member] | Ainos KY [Member]
Accrued Interest	$ 471	$ 335
Due Date	02/28/2023	11/25/2021
Annual Interest Rate, From Effective	1.85%	1.85%
Effective Date	5/25/2021	5/25/2021
Unpaid Principal Balance	$ 30,000	$ 30,000
Conversion Rate	$ 0.20	$ 0.20
Addition	$ 0	$ 30,000
15.21 [Member] | Ainos KY [Member]
Accrued Interest	$ 545	$ 385
Due Date	02/28/2023	11/28/2021
Annual Interest Rate, From Effective	1.85%	1.85%
Effective Date	5/28/2021	5/28/2021
Unpaid Principal Balance	$ 35,000	$ 35,000
Conversion Rate	$ 0.20
Addition		$ 35,000
Convertable Rate		$ 0.20
16.21 [Member] | Ainos KY [Member]
Accrued Interest	$ 4,486	$ 3,117
Due Date	02/28/2023	12/9/2021
Annual Interest Rate, From Effective	1.85%	1.85%
Effective Date	6/9/2021	6/9/2021
Unpaid Principal Balance	$ 300,000	$ 300,000
Conversion Rate	$ 0.20
Addition	$ 0	$ 300,000
Convertable Rate		$ 0.20
17.21 [Member] | Ainos KY [Member]
Accrued Interest	$ 1,535	$ 1,047
Due Date	02/28/2023	12/21/2021
Annual Interest Rate, From Effective	1.85%	1.85%
Effective Date	6/21/2021	6/21/2021
Unpaid Principal Balance	$ 107,000	$ 107,000
Conversion Rate	$ 0.20
Addition		$ 107,000
Convertable Rate		$ 0.20
18.21 [Member] | Ainos KY [Member]
Accrued Interest	$ 744	$ 498
Due Date	02/28/2023	1/2/2022
Annual Interest Rate, From Effective	1.85%	1.85%
Effective Date	7/2/2021	7/2/2021
Unpaid Principal Balance	$ 54,000	$ 54,000
Addition	$ 0	$ 54,000
Conversion Note	$ 0.20	$ 0.20
19.21 [Member] | Ainos KY [Member]
Accrued Interest	$ 1,289	$ 742
Due Date	02/28/2023	3/1/2022
Annual Interest Rate, From Effective	1.85%	1.85%
Effective Date	9/1/2021	912021
Unpaid Principal Balance	$ 120,000	$ 120,000
Addition	$ 0	$ 120,000
Conversion Note	$ 0.20	$ 0.20
20.21 [Member] | Ainos KY [Member]
Accrued Interest	$ 2,798	$ 1,429
Due Date	02/28/2023	3/28/2022
Annual Interest Rate, From Effective	1.85%	1.85%
Effective Date	9/28/2021	9/28/2021
Unpaid Principal Balance	$ 300,000	$ 300,000
Addition	$ 0	$ 300,000
Conversion Note	$ 0.20	$ 0.20
Total [Member]
Convertible And Other Notes Payable- Related Parties	$ 3,376,526	$ 3,376,526
Accrued Interest- Related Parties	39,540
Total [Member] | Ainos KY [Member]
Accrued Interest	23,192	25,224
Unpaid Principal Balance	3,000,000	3,000,000	670,991
Payment		363,490
Addition	0	3,069,025
Convertible And Other Notes Payable- Related Parties		3,000,000	3,000,000
Accrued Interest- Related Parties		9,507
21.21 [Member] | Ainos KY [Member]
Accrued Interest	$ 357	$ 129
Due Date	02/28/2023	5102022
Annual Interest Rate, From Effective	1.85%	1.85%
Effective Date	11/10/2021	11102021
Unpaid Principal Balance	$ 50,000	$ 50,000
Conversion Rate	$ 0.20	$ 0.20
Addition	$ 0	$ 50,000
22.21[Member] | Ainos KY [Member]
Accrued Interest	$ 2,851	$ 798
Due Date	02/28/2023	11/25/2022
Annual Interest Rate, From Effective	1.85%	1.85%
Effective Date	11/25/2021	11252021
Unpaid Principal Balance	$ 450,000	$ 450,000
Conversion Rate	$ 0.20	$ 0.20
Addition	$ 0	$ 450,000
23.21[Member] | Ainos KY [Member]
Accrued Interest	$ 1,840	$ 471
Due Date	02/28/2023	5/29/2022
Annual Interest Rate, From Effective	1.85%	1.85%
Effective Date	11/29/2021	11/29/2021
Unpaid Principal Balance	$ 300,000	$ 300,000
Conversion Rate	$ 0.20	$ 0.20
Addition	$ 0	$ 300,000
24.21[Member] | Ainos KY [Member]
Accrued Interest	$ 5,684	$ 124
Due Date	02/28/2023	6/29/2022
Annual Interest Rate, From Effective	1.85%	1.85%
Effective Date	12/29/2021	12292021
Unpaid Principal Balance	$ 1,219,000	$ 1,219,000
Conversion Rate	$ 0.20	$ 0.20
Addition	$ 0	$ 1,219,000
9.21 [Member] | StephenChen
Accrued Interest		$ 312
Due Date		4/14/2021
Annual Interest Rate, From Effective		0.13%
Effective Date		1/1/2021
Annual Interest Rate, Following Maturity		10%
Addition		$ 145,395
Payment		150,000
Convertible And Other Notes Payable- Related Parties		129,405	134,010
Payment Related Party		150,000
Addition Related Party		145,395
Accrued Interest Related Party		312
Dr. Stephen T. Chen [Member]
Accrued Interest	16,348	15,717
Unpaid Principal Balance	376,526	376,526	670,991
Payment	0	363,490
Addition		69,025
Dr. Stephen T. Chen [Member] | 1.16 [Member]
Accrued Interest	$ 6,050	$ 5,839
Due Date	Payable on demand	Payable on demand
Annual Interest Rate, From Effective	0.75%	0.75%
Effective Date	1/30/2016	1/30/2016
Unpaid Principal Balance	$ 114,026	$ 114,026	114,026
Conversion Rate	$ 0.17	$ 0.17
Dr. Stephen T. Chen [Member] | 2.16 [Member]
Accrued Interest	$ 10,298	$ 9,878
Due Date	Payable on demand	Payable on demand
Annual Interest Rate, From Effective	0.65%	0.65%
Effective Date	3/18/2016	3/18/2016
Unpaid Principal Balance	$ 262,500	$ 262,500	262,500
Conversion Rate	$ 0.19	$ 0.19
Dr. Stephen T. Chen [Member] | 3.19 [Member]
Accrued Interest		$ 0
Due Date		9/1/2020
Annual Interest Rate, From Effective		1.85%
Effective Date		912019
Unpaid Principal Balance		$ 0	39,620
Conversion Rate		$ 0.25
Payment		$ (39,620)
Annual Interest Rate, Following Maturity		10%
Dr. Stephen T. Chen [Member] | 4.19 [Member]
Accrued Interest		$ 0
Due Date		12/31/2020
Annual Interest Rate, From Effective		1.61%
Effective Date		1212019
Unpaid Principal Balance		$ 0	14,879
Conversion Rate		$ 0.25
Payment		$ (14,879)
Annual Interest Rate, Following Maturity		10%
Dr. Stephen T. Chen [Member] | 6.20 [Member]
Accrued Interest		$ 0
Due Date		1/1/2021
Annual Interest Rate, From Effective		1.85%
Effective Date		112020
Unpaid Principal Balance		$ 0	216,600
Conversion Rate		$ 0.25
Payment		$ 216,600
Annual Interest Rate, Following Maturity		10%
Dr. Stephen T. Chen [Member] | 7.20 [Member]
Accrued Interest		$ 0
Due Date		1/2/2021
Annual Interest Rate, From Effective		1.60%
Effective Date		112020
Unpaid Principal Balance		$ 0	23,366
Conversion Rate		$ 0.25
Payment		$ 23,366
Annual Interest Rate, Following Maturity		10%
Dr. Stephen T. Chen [Member] | 10.21 [Member]
Accrued Interest		$ 0
Due Date		4/1/2021
Annual Interest Rate, From Effective		1.85%
Effective Date		112021
Unpaid Principal Balance			0
Payment		$ 59,025
Annual Interest Rate, Following Maturity		1.85%
Convertible Rate		$ 0.25
Addition		$ 59,025
Dr. Stephen T. Chen [Member] | 11.21 [Member]
Accrued Interest		$ 0
Due Date		5/1/2021
Annual Interest Rate, From Effective		1.85%
Effective Date		412021
Unpaid Principal Balance			0
Conversion Rate		$ 0.25
Payment		$ 10,000
Annual Interest Rate, Following Maturity		10%
Addition		$ 10,000
i2China Management Group LLC [Member] | 5.19 [Member]
Unpaid Principal Balance		$ 0	16,000
Due Date		9/1/2020
Payment		$ 16,000
Accrued Interest		$ 0
Annual Interest Rate Following		10%
Annual Interest Rate From,effective		1.85%
Convertable Rate		$ 0.25
Effective Date		9/1/2019
i2China Management Group LLC [Member] | 8a.20 [Member]
Accrued Interest		$ 0
Due Date		1/1/2021
Effective Date		1/1/2020
Unpaid Principal Balance		$ 0	48,000
Payment		$ 48,000
Annual Interest Rate, Following Maturity		10%
Annual Interest Rate From,effective		1.85%
Convertable Rate		$ 0.25
i2China Management Group LLC [Member] | 8b.20 [Member]
Accrued Interest	$ 3,527	$ 3,137
Due Date	1/1/2021	1/1/2021
Annual Interest Rate, From Effective	1.85%	1.85%
Effective Date	1/1/2020	1/1/2020
Unpaid Principal Balance		$ 84,000	84,000
Annual Interest Rate, Following Maturity	10%	10%
i2China Management Group LLC [Member] | 11.21 [Member]
Accrued Interest		$ 0
Due Date		4/1/2021
Annual Interest Rate, From Effective		1.85%
Effective Date		112020
Payment		$ 37,000
Annual Interest Rate, Following Maturity		10%
Addition		$ 37,000
Convertable Rate		$ 0.25
i2China Management Group LLC [Member] | Total [Member]
Accrued Interest	$ 3,527	$ 25,224
Unpaid Principal Balance	84,000	84,000	734,991
Payment		464,490
Addition Related Party		37,000
Addition		3,106,025
Convertible And Other Notes Payable- Related Parties		10	64,000
Payment- Related Parties		101,000
i2China Management Group LLC [Member] | 9.21 [Member]
Accrued Interest	$ 354
Due Date	4/14/2021
Annual Interest Rate, From Effective	0.13%
Effective Date	1/1/2021
Unpaid Principal Balance	$ 129,405	129,405
Payment	$ 0
Annual Interest Rate, Following Maturity	10%
i2 China | 8b.20 [Member]
Payment		0
Addition		0
Notes Payable- Non-related Party		84,000	84,000
Notes Payable- Non-related Accrued		3,137
Total Notes Payable		213,405	$ 218,010
Total Notes Payable Addition		145,395
Total Notes Payable Payment		150,000
Total Notes Payable Accruel		$ 3,449

Convertible Notes Payable and_2

Convertible Notes Payable and Oayable (Details Narrative) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021	Dec. 31, 2020	Sep. 01, 2021
Accrued Interest			$ 28,673	$ 24,196
Total Convertible And Other Notes Payable	$ 4,389,931		3,589,931	953,001
Notes Payable For Related Parties			3,505,931	805,001
Total Principal And Accrued Interest Amount			$ 372,988
Conversion Price Per Shares	$ 0.01		$ 0.25
Interest Waived					$ 45,875
Repayment Of Debt			$ 150,000
Interest Expense	$ 16,687	$ 11,897	18,689	10,185
Dr. Stephen T
Interest Expense			21,727	10,702
Received Funding			214,420	$ 373,976
Ainos KY [Member]
Received Funding			$ 3,000,000

Related Party Transactions (Det

Related Party Transactions (Details)	12 Months Ended
	Dec. 31, 2021
ASE Technology Holding [Member]
Name Of The Related Party	ASE Technology Holding
Relationship	Affiliated company
Description	Sole owner of ASE Test Inc. which is Ainos KY’s board member and has more than 10% of the voting rights in Ainos KY
Taiwan Carbon Nano Technology Corporation ("TCNT") [Member]
Name Of The Related Party	Taiwan Carbon Nano Technology Corporation (“TCNT”)
Relationship	Affiliated company
Description	TCNT is the majority shareholder of Ainos KY
Dr. Stephen T. Chen [Member]
Name Of The Related Party	Dr. Stephen T. Chen
Relationship	Ainos’ former Chairman, President, CEO and CFO
Description	Shareholder with more than 5% of the Company voting rights in 2021 and 2020
Ainos, Inc. (Cayman Island) [Member]
Name Of The Related Party	Ainos, Inc. (Cayman Island) (“Ainos KY”)
Relationship	Affiliated company
Description	Ainos KY is the majority shareholder of the Company

Related Party Transactions (D_2

Related Party Transactions (Details Narrative) - USD ($)		3 Months Ended	12 Months Ended
	Mar. 11, 2022	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 30, 2021	Apr. 15, 2021
Related Party Transactions
Non convertible notes payable		$ 4,355,931	$ 3,505,931			$ 805,001
Covid-19 Antigen Rapid Test Kits		386,412	209,468	$ 0
Principal amount	$ 800,000	26,000,000
Development expenses		167,422
Purchase price		26,000,000
accrued payable		109,131
Convertible notes		3,000,000
Total Assets		$ 40,736,264	$ 40,822,161	$ 260,290
Total Assets Percentage			1%	1%
Capital Stock Holding Percentage			5%
Outstanding Capital Stock Percentage			5%
Common Stock Shares Issued		144,379,308	144,379,308	42,066,172	144,379,308	100,000,000
Common Stock Shares Issued Price Per Share						$ 0.20
Common Stock Shares Authorized						300,000,000
Issued And Outstanding Shares Of Common Stock Ownership Percentage						70.30%
Inventory			$ 183,444	$ 0
Product Development Expenses			205,883	$ 0
Account Payable			$ 65,156

Common Stock (Details Narrative

Common Stock (Details Narrative)) - USD ($)	Mar. 31, 2022	Dec. 31, 2021	Dec. 30, 2021	Dec. 27, 2021	Jun. 30, 2021	Apr. 15, 2021	Apr. 07, 2021	Dec. 31, 2020
Common Stock, Capital Shares Reserved For Future Issuance				413,368
Common Stock, Shares Authorized						300,000,000
Common Stock, Shares, Issued, Total	144,379,308	144,379,308	144,379,308			100,000,000		42,066,172
Shares Issued, Price Per Share						$ 0.20
Chen Agreement [Member]
Common Stock, Shares, Issued, Total					5,342
Common Stocks [Member]
Common Stock, Shares Outstanding And Reserved	26,900,000	163,915,625
Reserved For Conversion Of Convertible Debt To Stock	144,379,308	17,213,700
Future Exercise Of Stock Options	550,000	550,000
Shares Reserved For Warrant Conversion	452,617	452,617
Common Stock, Capital Shares Reserved For Future Issuance	17,285,625	1,320,000
RSUs for non-employee directors	1,320,000,000,000
Common Stock, Shares Authorized	300,000,000	300,000,000
Common Stock, Shares, Issued, Total	163,987,550	144,379,308
Ainos KY [Member]
Common Stock, Shares, Issued, Total						100,000,000
Shares Issued, Price Per Share						$ 0.20
StephenChen
Common Stock, Shares, Issued, Total							48,077
Bernard Cohen [Member]
Common Stock, Shares, Issued, Total					107		5,769
Lawrence Lin [Member]
Common Stock, Shares, Issued, Total				2,946	3,846		11,538
John Junyong Lee [Member]
Common Stock, Shares, Issued, Total				28,826	21,926		109,038
Ya-Ju [Member]
Common Stock, Shares, Issued, Total					20,000
Shares Issued, Price Per Share					$ 0.38
Proceed From Issuance Of Common Stock					$ 7,600
Daniel Fisher [Member]
Common Stock, Shares, Issued, Total					150,400
Shares Issued, Price Per Share					$ 0.38
Proceed From Issuance Of Common Stock					$ 57,152
Calibre Corporation [Member]
Common Stock, Shares, Issued, Total				1,491,953
Shares Issued, Price Per Share				$ 0.25
Aggregate Principal And Accrued Interest Amount				$ 372,988
i2China Management Group LLC [Member]
Common Stock, Shares, Issued, Total				413,368
Shares Issued, Price Per Share				$ 0.25
Aggregate Principal And Accrued Interest Amount				$ 103,342

Preferred Stock (Details Narrat

Preferred Stock (Details Narrative) - shares	Mar. 31, 2022	Dec. 31, 2021	Dec. 30, 2021	Dec. 31, 2020
Common Stock
Preferred Stock, Shares Authorized	10,000,000	10,000,000	10,000,000,000,000	10,000,000
Preferred Stock, Shares Authorized	10,000,000	10,000,000	10,000,000,000,000	10,000,000
Preferred Stock, Shares Issued	0	0	0	0
Preferred Stock, Shares Outstanding		0		0

Stock Option and Stock Plans (D

Stock Option and Stock Plans (Details)	12 Months Ended
	Dec. 31, 2021 shares
Amarillo Biosciences, Inc., 2018 Employee Stock Option Plan
Issue Date Range	9/26/18 - 9/26/28
Total Shares Authorized	1,000,000
Shares Issued	950,000
Share Remaining	0
Amarillo Biosciences, Inc., 2018 Officers, Directors, Employees, and Consultants Nonqualified Stock Option Plan
Issue Date Range	9/26/18 - 9/26/28
Total Shares Authorized	4,000,000
Shares Issued	4,495,000
Share Remaining	0

Stock Option and Stock Plans _2

Stock Option and Stock Plans (Details 1) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Weighted Average Exercise Price Granted	$ 0.38	$ 0
Weighted Average Exercise Price Exercised	0.38	0
Weighted Average Exercise Price Expired Or Forfeited	0.38	0
Weighted Average Exercise Price Outstanding, Ending	0.38	$ 0.38	$ 0.38
Weighted Average Exercise Price Vested	$ 0.38
Weighted Average Remaining Contactual Term Outstanding	9 years 6 months 14 days	7 years	8 years
Weighted Average Remaining Contactual Term Granted	10 years
Weighted Average Remaining Contactual Term Vested	6 years 8 months 26 days
Aggregate Intrinsic Value Outstanding, Ending	$ 0	$ 0
Weighted Average Exercise Price Outstanding, Beginning	$ 0.38	$ 0.38
Aggregate Intrinsic Value Granted	$ 0	$ 0
Aggregate Intrinsic Value Exercised	$ 0	$ 0
Aggregate Intrinsic Value Expired Or Forfeited	$ 0	$ 0
Aggregate Intrinsic Value Vested	$ 0
Qualified
Options Outstanding, Beginning	850,000	850,000
Options Exercised	20,000	0
Options Granted	0
Options Expired Or Forfeited	780,000	0
Options Outstanding, Ending	50,000	850,000	850,000
Options Vested	30,000
Nonqualified
Options Outstanding, Beginning	3,807,000	3,807,000
Options Exercised	150,400	0
Options Granted	500,000
Options Expired Or Forfeited	3,656,600	0
Options Outstanding, Ending	500,000	3,807,000	3,807,000
Options Vested	0

Stock Option and Stock Plans _3

Stock Option and Stock Plans (Details Narrative) - USD ($)	1 Months Ended	12 Months Ended
	Sep. 26, 2021	Dec. 31, 2021	Sep. 28, 2021
Unrecognized Option Expense		$ 410,022
Unrecognized Option Expense Period Of Recognition		2 years 6 months 29 days
Options To Acquire Shares Of Common Stock		550,000
Volatility Rate		276%
Term		5 years
Discount Percentage		2.96%
Stock Incentive Plan Description		The aggregate number of shares which may be issued pursuant to awards under the Plan is 20,000,000 shares of Common Stock (the “Plan Share Reserve”), subject to adjustments as provided in the Plan. The number of shares underlying any award granted under 2018 ESOP or 2018 NQSOP (the “Prior Plans”) that expires, terminates or is canceled or forfeited for any reason whatsoever under the terms of the Prior Plans, will increase the Plan Share Reserve. Each Award granted under the Plan will reduce the Plan Share Reserve by the number of shares underlying the award. No more than 10,000,000 shares may be issued in the aggregate pursuant to the exercise of incentive stock options granted under the Plan. The maximum number of shares subject to awards granted during a single fiscal year to any non-employee director, taken together with any cash fees paid to such director during the fiscal year, will not exceed $600,000 in total value (calculating the value of any such awards based on their grant date fair value for financial reporting purposes)
Option [Member]
Shares Price Per Shares		$ 0.38
Options Exercisable Term Period		10 years
Vesting Period		5 years
Vesting Percentage		20%
2018-ESOP
Number Of Shares Of Common Stock Issued		1,000,000
2018-NQSOP
Number Of Shares Of Common Stock Issued	4,000,000	550,000
Shares Price Per Shares	$ 0.382
Options Exercisable Term Period	10 years
Vesting Period	5 years
Vesting Percentage	20%
2021 Employee Stock Purchase Plan
Number Of Shares Of Common Stock Issued			750,000

Warrants (Details Narrative)

Warrants (Details Narrative)	12 Months Ended
	Dec. 31, 2021 USD ($) $ / shares shares
Warrants, Term	5 years
Warrant [Member]
Warrant Exercise Price | $ / shares	$ 0.27
Number Of Warrant Purchase Common Stock | shares	452,617
Warrants Outstanding | $	$ 68,349
Warrants Outstanding, Term	60 years
Warrant [Member] | Measurement Input, Price Volatility [Member]
Warrants, Volatility	201%
Warrant [Member] | Measurement Input, Expected Term [Member]
Warrants, Term	5 years
Warrant [Member] | Measurement Input, Discount Rate [Member]
Warrants, Discount Rate	0.11%

Income Taxes (Details)

Income Taxes (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Income Taxes
Provision (benefit) At Statutory Rate	$ (816,000)	$ (305,000)
Permanent Differences	0	1,000
Temporary Differences	206,000	79,000
Change In Valuation Allowance	$ 610,000	$ 225,000

Income Taxes (Details 1)

Income Taxes (Details 1) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Deferred Tax Assets:
Net Operating Loss Carryforward	$ 4,357,000	$ 4,328,270
Other Assets	248,000	217,000
Deferred Tax Assets	4,605,000	4,545,270
Deferred Tax Liabilities:
Deferred Tax Liabilities	0	0
Net Deferred Tax Assets	4,605,000	4,545,270
Valuation Allowance	$ (4,605,000)	$ (4,545,270)

Income Taxes (Details Narrative

Income Taxes (Details Narrative)	12 Months Ended
	Dec. 31, 2021 USD ($)
Income Taxes
Net Operating Loss Carryforwards	$ 20,747,517
U.s. Federal Income Tax, Rate	21%

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative)			1 Months Ended		3 Months Ended	12 Months Ended
	Aug. 11, 2021 USD ($) shares	Aug. 01, 2021 USD ($) shares	Apr. 15, 2021 USD ($)	Jan. 02, 2021 USD ($)	Mar. 31, 2022 USD ($)	Dec. 31, 2021 USD ($) ft²	Dec. 31, 2020 USD ($)	Mar. 11, 2022 USD ($)	Dec. 27, 2021 USD ($) $ / shares shares	Nov. 25, 2020 shares	Jan. 01, 2020 USD ($)
Commitments and Contingencies
Office Space | ft²						1,250
Product Development Facility Area | ft²						8,517
Contract Amount For Construction In Progress						$ 670,000
Outstanding Contract Amount For Construction In Progress						464,000
Monthly Salary	$ 230,000	$ 12,000	$ 250,000
Monthly Salary Equivalent To Taiwan Dollors	$ 8,214		$ 8,929
Annual Compensation In The Form Of Cash Percentage Range	10-30		10-30
Vesting Stock Options | shares		500,000
Bonus Of Shares | shares	10,000
Warrants Issued | shares										452,617
Non-convertible Note Issued Principal Amount								$ 800,000			$ 84,000
Converted Into Shares Of Common Stock | shares									413,368
Conversion Price Of Per Share | $ / shares									$ 0.25
Annual Salary				$ 70,000		240,000	$ 240,000
Shares Payable Quarterly Based On The Average Share Price				$ 1,000		100,000	100,000
Principal And Accrued Interest Amount									$ 103,342
Covid-19 Antigen Rapid Test Kits					$ 386,412	$ 209,468	$ 0

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)		1 Months Ended
	Mar. 11, 2022	Jan. 30, 2022	Mar. 30, 2027	Mar. 31, 2022	Jan. 29, 2022	Dec. 31, 2021	Jan. 01, 2020
Subsequent Events
Intellectual Property Assets Purchase Price					$ 26,000,000
Convertible Promissory Note Principal Amount		$ 26,000,000	$ 500,000	$ 26,000,000
Convertible Note Payable In Cash Date		Jan. 30, 2027
Initial Public Offering Price Of The Offering Percentage		80%	80%
Unpaid Principal And Accrued Interest, And A Maturity Date	Feb. 28, 2023
Unpaid Principal And Accrued Interest Rate		1.85%
Non-convertible Note Issued Principal Amount	$ 800,000						$ 84,000
Unpaid Principal Amount						$ 3,000,000
Accrued Interest						$ 9,507

Current Convertible Notes Pay_3

Current Convertible Notes Payable and Other Notes Payable (Details) - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Total non-convertible notes payable	$ 1,013,405	$ 213,405
Total non-convertible notes payable accrued interest	5,016
Total non-convertible notes payable addition	800,000
Total convertible and non-convertible	4,389,931	3,589,931	$ 953,001
Total convertible and non-convertible addition	800,000	3,251,420
Total convertible and non-convertible Payment	0	614,490
Total convertible and non-convertible accrued	44,556	28,673
Non-convertible notes payable-related party	929,405	129,405
Non-convertible notes payable-related party accrued interest	1,489
Non-convertible notes payable-related party addition	800,000
Accrued Interest		28,673	24,196
12.21 [Member] | Ainos KY [Member]
Accrued Interest	$ 257	$ 189
Due Date	02/28/2023	10/27/2021
Annual interest rate, From effective	1.85%	1.85%
Effective Date	4/27/2021	4/27/2021
Unpaid principal balance	$ 15,000	$ 15,000	15,000
Conversion rate	$ 0.20	$ 0.20
Addition	$ 0	$ 15,000
13.21 [Member] | Ainos KY [Member]
Accrued Interest	$ 335	$ 243
Due Date	02/28/2023
Annual interest rate, From effective	1.85%	1.85%
Effective Date	5/5/2021	5/5/2021
Unpaid principal balance	$ 20,000	$ 20,000
Conversion rate	$ 0.20	$ 0.20
Addition		$ 20,000
14.21 [Member] | Ainos KY [Member]
Accrued Interest	$ 471	$ 335
Due Date	02/28/2023	11/25/2021
Annual interest rate, From effective	1.85%	1.85%
Effective Date	5/25/2021	5/25/2021
Unpaid principal balance	$ 30,000	$ 30,000
Conversion rate	$ 0.20	$ 0.20
Addition	$ 0	$ 30,000
15.21 [Member] | Ainos KY [Member]
Accrued Interest	$ 545	$ 385
Due Date	02/28/2023	11/28/2021
Annual interest rate, From effective	1.85%	1.85%
Effective Date	5/28/2021	5/28/2021
Unpaid principal balance	$ 35,000	$ 35,000
Conversion rate	$ 0.20
Addition		35,000
16.21 [Member] | Ainos KY [Member]
Accrued Interest	$ 4,486	$ 3,117
Due Date	02/28/2023	12/9/2021
Annual interest rate, From effective	1.85%	1.85%
Effective Date	6/9/2021	6/9/2021
Unpaid principal balance	$ 300,000	$ 300,000
Conversion rate	$ 0.20
Addition	$ 0	300,000
17.21 [Member] | Ainos KY [Member]
Accrued Interest	$ 1,535	$ 1,047
Due Date	02/28/2023	12/21/2021
Annual interest rate, From effective	1.85%	1.85%
Effective Date	6/21/2021	6/21/2021
Unpaid principal balance	$ 107,000	$ 107,000
Conversion rate	$ 0.20
Addition		107,000
18.21 [Member] | Ainos KY [Member]
Accrued Interest	$ 744	$ 498
Due Date	02/28/2023	1/2/2022
Annual interest rate, From effective	1.85%	1.85%
Effective Date	7/2/2021	7/2/2021
Unpaid principal balance	$ 54,000	$ 54,000
Addition	$ 0	$ 54,000
Conversion Note	$ 0.20	$ 0.20
19.21 [Member] | Ainos KY [Member]
Accrued Interest	$ 1,289	$ 742
Due Date	02/28/2023	3/1/2022
Annual interest rate, From effective	1.85%	1.85%
Effective Date	9/1/2021	912021
Unpaid principal balance	$ 120,000	$ 120,000
Addition	$ 0	$ 120,000
Conversion Note	$ 0.20	$ 0.20
20.21 [Member] | Ainos KY [Member]
Accrued Interest	$ 2,798	$ 1,429
Due Date	02/28/2023	3/28/2022
Annual interest rate, From effective	1.85%	1.85%
Effective Date	9/28/2021	9/28/2021
Unpaid principal balance	$ 300,000	$ 300,000
Addition	$ 0	$ 300,000
Conversion Note	$ 0.20	$ 0.20
Total [Member]
Convertible and other notes payable- related parties	$ 3,376,526	$ 3,376,526
Accrued Interest- related parties	39,540
Total [Member] | Ainos KY [Member]
Accrued Interest	23,192	25,224
Unpaid principal balance	3,000,000	3,000,000	670,991
Payment		363,490
Addition	0	3,069,025
Convertible and other notes payable- related parties		3,000,000	3,000,000
Accrued Interest- related parties		9,507
21.21 [Member] | Ainos KY [Member]
Accrued Interest	$ 357	$ 129
Due Date	02/28/2023	5102022
Annual interest rate, From effective	1.85%	1.85%
Effective Date	11/10/2021	11102021
Unpaid principal balance	$ 50,000	$ 50,000
Conversion rate	$ 0.20	$ 0.20
Addition	$ 0	$ 50,000
22.21[Member] | Ainos KY [Member]
Accrued Interest	$ 2,851	$ 798
Due Date	02/28/2023	11/25/2022
Annual interest rate, From effective	1.85%	1.85%
Effective Date	11/25/2021	11252021
Unpaid principal balance	$ 450,000	$ 450,000
Conversion rate	$ 0.20	$ 0.20
Addition	$ 0	$ 450,000
23.21[Member] | Ainos KY [Member]
Accrued Interest	$ 1,840	$ 471
Due Date	02/28/2023	5/29/2022
Annual interest rate, From effective	1.85%	1.85%
Effective Date	11/29/2021	11/29/2021
Unpaid principal balance	$ 300,000	$ 300,000
Conversion rate	$ 0.20	$ 0.20
Addition	$ 0	$ 300,000
24.21[Member] | Ainos KY [Member]
Accrued Interest	$ 5,684	$ 124
Due Date	02/28/2023	6/29/2022
Annual interest rate, From effective	1.85%	1.85%
Effective Date	12/29/2021	12292021
Unpaid principal balance	$ 1,219,000	$ 1,219,000
Conversion rate	$ 0.20	$ 0.20
Addition	$ 0	$ 1,219,000
26.22[Member] | Ainos KY [Member]
Accrued Interest	$ 1,135
Due Date	3/31/2023
Annual interest rate, From effective	1.85%
Effective Date	3/4/2022
Unpaid principal balance	$ 800,000
Addition	800,000
Dr. Stephen T. Chen [Member]
Accrued Interest	16,348	15,717
Unpaid principal balance	376,526	376,526	670,991
Payment	0	363,490
Dr. Stephen T. Chen [Member] | 1.16 [Member]
Accrued Interest	$ 6,050	$ 5,839
Due Date	Payable on demand	Payable on demand
Annual interest rate, From effective	0.75%	0.75%
Effective Date	1/30/2016	1/30/2016
Unpaid principal balance	$ 114,026	$ 114,026	114,026
Conversion rate	$ 0.17	$ 0.17
Dr. Stephen T. Chen [Member] | 2.16 [Member]
Accrued Interest	$ 10,298	$ 9,878
Due Date	Payable on demand	Payable on demand
Annual interest rate, From effective	0.65%	0.65%
Effective Date	3/18/2016	3/18/2016
Unpaid principal balance	$ 262,500	$ 262,500	262,500
Conversion rate	$ 0.19	$ 0.19
i2China Management Group LLC [Member] | 8b.20 [Member]
Accrued Interest	$ 3,527	$ 3,137
Due Date	1/1/2021	1/1/2021
Annual interest rate, From effective	1.85%	1.85%
Effective Date	1/1/2020	1/1/2020
Unpaid principal balance		$ 84,000	84,000
Annual interest rate, Following maturity	10%	10%
consulting fee	$ 84,000	$ 84,000
i2China Management Group LLC [Member] | Total [Member]
Accrued Interest	3,527	25,224
Unpaid principal balance	84,000	84,000	$ 734,991
Payment		464,490
i2China Management Group LLC [Member] | 9.21 [Member]
Accrued Interest	$ 354
Due Date	4/14/2021
Annual interest rate, From effective	0.13%
Effective Date	1/1/2021
Unpaid principal balance	$ 129,405	$ 129,405
Payment	$ 0
Annual interest rate, Following maturity	10%

Current Convertible Notes Pay_4

Current Convertible Notes Payable and Other Notes Payable (Details Narrative) - USD ($)		3 Months Ended	12 Months Ended
	Mar. 11, 2022	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Convertible Notes Payable
Total interest expense		$ 15,883	$ 11,897
Total Convertible and other notes payable		4,389,931	3,589,931	$ 953,001
Cumulative related accrued interest		44,556	$ 28,673
Principal amount	$ 800,000	26,000,000
Convertible notes		$ 3,000,000

Non-Current Convertible Notes_2

Non-Current Convertible Notes Payable (Details Narrative) - USD ($)	3 Months Ended	24 Months Ended
	Mar. 31, 2022	Dec. 31, 2021	Mar. 30, 2027	Mar. 28, 2022	Jan. 30, 2022
Non-Current Convertible notes payable	$ 26,900,000	$ 0
Conversion Price Per Shares	$ 0.01	$ 0.25
Convertible Promissory Note	$ 26,000,000		$ 500,000		$ 26,000,000
Yun Han Liao [Member]
Convertible note issued	$ 50,000
Chih Heng Tsai [Member]
Convertible note issued				$ 850,000